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There is a bidirectional interaction between the gut and the brain, termed the gut-brain axis 
(GBA), involving e.g. the gut microbiota, and connecting the peripheral intestinal elements to 
the central nervous system (CNS). The GBA is increasingly recognized as a vital factor in the 
development and prognosis of neurological and psychiatric disorders. Of particular interest in 
this thesis is the signaling from gut microbiota to brain and back which is enabled through 
neural, endocrine, immune, and humoral pathways. 
Studies in germ-free and antibiotic-treated animal models have created a significant body of 
knowledge on the GBA and its role in regulating behavior. There are fewer studies using human 
subjects or with human materials. 
This thesis is focused on both clinical and biological aspects of GBA in attention-deficit 
hyperactivity disorder (ADHD). ADHD is a common childhood-onset psychiatric and 
neurodevelopmental disorder, which is characterized by having problems with paying attention 
and/or excessive activity and impulsivity, along with impairments on daily function and 
emotion regulation. ADHD is highly heritable and has high comorbidity with other psychiatric 
disorders and a higher-than-normal co-occurrence with some inflammatory disorders (e.g. 
asthma, eczema, rhinitis, celiac disease). However, ADHD is diagnosed primarily based on 
clinical observations of behaviors. Biomarkers for diagnosis and approaches for new therapy 
are lacking and the pathophysiology is poorly understood.  
This thesis consists of five studies attempting to explore some aspects of the GBA in 
neurodevelopmental and psychiatric disorders, with a focus on ADHD, utilizing a nationwide 
population-based cohort, a case-control design, a randomized controlled trial (RCT) and an in 
vitro model. It covers different aspects of the GBA, including gut microbiota and related 
antibiotic exposure, probiotic and prebiotic intervention, derived metabolites, inflammatory 
mediators, as well as the associations with clinical observations. 
Specifically, in Study I, we investigated whether exposure to antibiotic drugs, in utero and first 
two years after birth was associated with a risk for childhood-onset psychiatric disorders. Using 
Finnish nationwide registers, we found that antibiotic exposure was associated with a 10–50%  
increased risk for development of sleep disorders, ADHD, conduct disorders, mood disorders 
and anxiety disorders, which were accompanied by an increased risk for psychotropic drug use 
in childhood. The association with prenatal antibiotic exposure was neither explained 
completely by confounding factors related to family, nor by factors related to maternal 
infections. 
In Study II, we used a case-control design to study plasma levels of four inflammatory 
mediators: C-reactive protein (CRP), serum amyloid A (SAA), soluble intercellular adhesion 
molecule 1 (sICAM-1) and soluble vascular cell adhesion molecule 1 (sVCAM-1) in ADHD 
and their associations with medication and clinical symptoms. We found that ADHD patients 
  
had higher levels of sICAM-1 and sVCAM-1 than healthy controls, especially in children 
currently on ADHD medication. Among adult participants with ADHD, sICAM-1 levels were 
positively associated with comorbid autism symptoms, and CRP levels were associated with 
GI symptoms and emotion dysregulation. 
In Study III, a double-blind RCT was conducted to determine whether a synbiotic (Synbiotic 
2000), consisting of a mixture of three lactic acid bacteria and four fibers had effects on 
symptoms, daily functioning, and comorbid traits in ADHD patients. We found that Synbiotic 
2000, compared to placebo, significantly reduced typical restricted, repetitive and stereotyped 
behaviors of autism symptoms in children, and alleviated problems with goal-directed behavior 
of emotion regulation in adults. The effects on autism symptoms and problems with emotion 
regulation were stronger in the subgroup with higher sVCAM-1 levels.  
In Study IV, using data from the same RCT as in study III, we investigated the effects of 
Synbiotic 2000 on plasma levels of immune activity markers and short-chain fatty acids 
(SCFAs) in ADHD. Adults with ADHD had at baseline higher levels of pro-inflammatory 
vascular adhesion molecules (sICAM-1, sVCAM-1) and lower levels of the anti-inflammatory 
interleukin (IL)-10 compared to controls. Synbiotic 2000, compared to placebo treatment, was 
associated with reduced the levels of IL-12/IL-23p40 in children on ADHD medication, and 
suggestively associated with reduced sICAM-1 levels and increased propionic acid levels in 
children. Moreover, in adult patients we found lower baseline levels compared to controls of 
formic acid and propionic acid. No obvious effects of Synbiotic 2000 were found on plasma 
levels of SCFAs. However, we found IL-10 levels correlating positively with formic acid and 
acetic acid at baseline for both children and adults with ADHD. In child patients, sVCAM-1 
correlated negatively with acetic acid and propionic acid while sICAM-1 correlated negatively 
with acetic acid. In adult patients, a negative correlation was observed between sVCAM-1 and 
formic acid at baseline. 
In Study V, an in vitro model was used to explore the effects of three SCFAs: acetate, 
propionate and butyrate, on cell growth and cell death of early stage human neural progenitor 
cells (hNPCs). We found that acetate, propionate and butyrate at low µM levels, relevant to 
physiological levels, significantly increased the proliferation of hNPCs and induced more cells 
to undergo mitosis, while the SCFAs at high mM levels had toxic effects on hNPCs. In support 
of this, the SCFA exposure to hNPCs changed the expression of genes involved in 
neurogenesis, proliferation and apoptosis. 
These studies provide support of a role of components influenced by the GBA, including gut 
microbiota, immune activity markers and bacterial metabolites in clinical and biological 
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Attention-deficit hyperactivity disorder (ADHD), was first described as a disorder in 1902 by 
the pediatrician George Frederic Still, saying “an abnormal defect of moral control in children” 
1. The children affected by the disorder behaved differently from a typical child and could not 
control themselves, while still having normal intelligence. ADHD was recognized as a 
hyperkinetic impulse disorder in the second edition of “Diagnostic and Statistical Manual of 
Mental Disorders” (DSM) published in 1968 by the American Psychological Association. 
DSM is a manual, which lists all of the defined mental disorders, including the descriptions of 
symptoms, diagnosis criteria, known causes, risk factors, and treatments, and continuously 
updated versions have been used by clinicians and researchers. Until the revised version of the 
third edition of the DSM (DSM-III) published in 1987, the description ADHD was redefined 
into a single term that combined three symptoms, including inattentiveness, impulsivity and 
hyperactivity. In the current DSM-V used today, ADHD is added to the neurodevelopmental 
disorders and classified into three subtypes: predominantly inattention, predominantly 
hyperactivity-impulsivity and combined manifestation 2. At the same time, a global 
classification system by the World Health Organization (WHO), International Classification of 
Diseases (ICD) as analogous to DSM, is being used as the main classification system among 
healthcare professionals in e.g. Europe, with the 10th version (ICD-10) currently used for 
ADHD 2.  
The number of ADHD cases started to increase remarkably in the 1990s. This can probably be 
explained by more awareness and reporting of symptoms by parents and school teachers, more 
efficient diagnosis, better access to healthcare and more children actually developing ADHD 
3. Scientific findings have pointed to strong roles of genetic factors and some roles of 
environmental factors in the development of ADHD 4. Researchers and psychiatrists are 
dedicated to figure out the underlying causes as well as possible diagnostic biomarkers and 
treatment targets for the disorder.  
In recent decades, research into the communication between the gut microbiota 
(microorganisms such as bacteria, fungi, viruses and archaea) and the brain, summarized as 
gut-brain axis (GBA) or microbiota-gut-brain axis (MGBA), has started to elucidate causal 
roles of the gut microbiota on brain function and behaviors as well as the underlying molecular 
interactions. Animal models, typically germ-free and antibiotic drug-treated mice, implied the 
microbiota for influencing the endocrine hypothalamic–pituitary–adrenal (HPA) axis, behavior 
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regulation and brain development 5-8. More molecular evidence involving brain-derived 
neurotrophic factor (BDNF), neurotransmitters, microbial metabolites (e.g. tryptophan, short-
chain fatty acids (SCFAs)) and immune activity markers, supported the gut microbiota–brain 
communication 7, 9, 10. Research on the GBA is growing in the field of psychiatric, 
neurodevelopmental and neurodegenerative disorders 11. 
The overall aim of this thesis was to explore certain aspects of the GBA in neurodevelopment 
with a focus on ADHD, and to explore a new adjuvant therapeutic strategy for ADHD. In this 
thesis, I will start by introducing the current knowledge and major background on ADHD and 
GBA.  
 
1.1 ADHD  
1.1.1 Clinical manifestations  
ADHD is a common neurodevelopmental disorder among children and adolescents, with the 
core symptoms indicated by the name: inattention and/or hyperactivity-impulsivity. The 
disorder has generally an onset age before 12 years and may continue throughout life or not be 
diagnosed until adulthood 12. At present, the widely used and standard diagnosis tool is the 
DSM-V or ICD-10 criteria, within categories 314.0X or F90.X 13. To get a diagnosis according 
to the DMS-V, at least six inattentive or hyperactive-impulsive symptoms for children up to 16 
years, five or more symptoms for individuals older than 16 years and adults, must be present 
for more than 6 months. Several symptoms must be present before 12 years of year and lead to 
impairments in at least two significant areas of functioning, such as at work, school, family and 
social settings 2. Emotion dysregulation is listed as a characteristic feature of ADHD according 
to DSM-V, which can support the diagnosis. Emotion dysregulation refers to inability to 
manage negative emotions such as anger, sadness and fear. DERS is a widely-used scale to 
measure emotion regulation difficulties, which include five different domains: lack of 
emotional clarity (e.g. confused about the feeling), difficulties in goal-directed behavior (e.g. 
difficult to get work done), difficulties in impulse control (e.g. behaviour outbursts), limited 
access to effective emotional regulation strategies (e.g. unable to make yourself feeling better), 
non-acceptance of emotional responses (e.g. ashamed of feeling that way) 14. From a clinical 
perspective, the predominant features of ADHD in adults are different from those in children, 
showing less obvious hyperactivity-impulsivity symptoms and more inattentive symptoms 15. 
Similar to other complex psychiatric disorders, ADHD presents with marked heterogeneity. 
Variation among individuals with a diagnosis of ADHD is found on core symptom 
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combinations, levels of function impairments and comorbidities. ADHD has a high 
comorbidity with other neuropsychiatric and neurological/somatic conditions such as Tourette 
syndrome, oppositional defiant and conduct disorder, autism spectrum disorder (ASD), mood 
disorders, anxiety disorder, learning disability, intellectual disability and sleep disorder 16-19, as 
well as epilepsy, migraine, asthma, rhinitis, eczema, celiac disease and obesity 20-22. About 15–
25% of young individuals with ADHD demonstrate ASD traits and symptoms, and 12.4% of 
them have an ASD diagnosis 19. Meanwhile, for children who have ASD the comorbidity rates 
for ADHD is 40–70% 19. Individuals diagnosed with ASD show deficits in the aspects of social 
interaction and communication and/or have restricted and repetitive patterns of behavior, 
activities or interests, which can cause significant functional impairments 19. 
1.1.2 Epidemiology 
In 2015, the globally estimated number of individuals to be diagnosed with ADHD was about 
51.1 million 23. A meta-analysis on the prevalence of ADHD diagnosed by DSM-IV estimated 
5.9-7.1% in children and adolescents and slightly lower 5% in adults 24. While other 
epidemiological studies reported much lower prevalence for both children (3.4%) and adults 
(2.5%) 25, 26. The variability for the estimated prevalence was mostly due to methodological 
procedures and diagnostic criterions, but not significantly associated with geographical 
locations 27, 28. Over the last three decades, there has been no increase in the population rate of 
ADHD using the standard criteria 28. A newly published article reported trends for an increasing 
rate of ADHD diagnosis among adults in United States 29, which was confirmed in 
Scandinavian counties 3, 30. The global increase in prevalence of ADHD cannot be attributed to 
insurance coverage or health care systems in different countries 29. However, the rate decreased 
with age, since the core features of ADHD tend to decline with age 15, 26. Up to 65% of pediatric 
ADHD patients persist to have symptoms in adulthood 15. In children, ADHD is 3-9 times more 
common in boys than girls, while in adult population the sex ratio is more balanced 15, 24, 26. 
ADHD is often overlooked in girls, one reason of which is the different clinical features 
between girls and boys, similar as in ASD 31-33. This may partially explain the sex difference 
in prevalence among children. 
1.1.3 Pathophysiology 
ADHD is a complex disorder and could have long-term outcomes. Although ADHD is one of 
most studied psychiatric disorders, the pathophysiology of ADHD is not very clear. Growing 
number of evidence has shown that genetic and environmental risk factors, as well as their 
interactions play important roles in the etiology of the disorder. A twin study demonstrated a 
heritability of 70–80% for ADHD in both children and adults 34. A family-based study indicated 
 
4 
that siblings of individuals with ADHD have much higher risk to develop the disorder than 
siblings of non-ADHD individuals 35. As with the heterogeneity and multifactorial nature, 
ADHD is primarily attributed to multiple common genetic variants (single nucleotide 
polymorphisms). Recently, a meta-analysis of genome-wide association studies (GWAS) 
found 304 genetic variants in 12 loci that reached significance in ADHD and some of the loci 
were in, or close to genes (e.g. DUSP6, SORCS3, FOXP2) involved in neurodevelopment 36. 
Data from 10 GWAS in ADHD suggested the involvement of genes related to 
neurotransmission, neural growth, cell adhesion, neurotransmitter system and synaptic 
plasticity, which was in line with classical candidate gene studies 4. Biological pathway and 
network analysis on 105 ADHD-candidate genes identified 14 genes that were highly involved 
in nitric oxide synthase pathway and α-1 adrenergic pathway and were actively expressed in 
the cerebellum and cortex 37. In addition, more rare genetic variants (copy number variants) 
have been shown to be associated with ADHD 38. ADHD-associated copy number variants 
span genes that encode the nicotinic α7 acetylcholine receptor subunit, neuropeptide Y and 
several glutamate receptor genes 39, 40. The high heritability of ADHD is due to polygenic 
components and approximately 33% of the heritability is explained by the common genetic 
variants 38. The polygenic architecture in ADHD is similar to other neuropsychiatric disorders 
such as ASD and schizophrenia 41, 42. 
Reported environmental risk factors for ADHD include prenatal/perinatal exposures: maternal 
stress, smoking, alcohol use, psychopathology, obesity, infections and premature birth and low 
birth weight; postnatal exposures: anti-infective agents, environmental chemicals (e.g. lead and 
organophosphates, nicotine, alcohol), socioeconomic factors (e.g. low income, family 
adversity, and harsh parenting,) as well as dietary factors (e.g. mineral deficiency, Omega-3 
fatty acid deficiency) 43-45. The prenatal exposures, especially the first trimester (1-12 
gestational week), probably have the largest impacts on neurodevelopment due to the more 
pronounced vulnerability when complex development is happening 46. Since gestational week 
5, the embryo starts to form the neural tube, early nervous system begins to develop and the 
major structures of the fetus is present by the end of week 11. The development of the neural 
system runs through almost all 3 trimesters and is complete several years after birth. The 
environmental risks and the outcomes can be determined by genetic properties of the disorder, 
and on the other hand, environmental factors can influence the genetically associated 
phenotypes via epigenetic modifications 4.  
Moreover, employment of neuroimaging techniques (e.g. CT, MRI, fMRI) has showed brain 
structure and function abnormalities, which are involved in the pathophysiology of ADHD. 
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Alterations in brain regions, like the white matter, gray matter, basal ganglia, limbic areas and 
neural network for cognition, attention and executive functions were associated with ADHD 2.  
1.1.4 Treatment 
Currently, there are pharmacological and non-pharmacological treatments for the management 
of symptoms and function deficits in ADHD, but no therapeutic strategy to cure the disorder 
entirely. The stepwise treatment options according to specific guidelines vary a bit 
geographically. In Europe, pharmacotherapy is widely accepted as first line treatment for both 
children and adults, which include stimulants (methylphenidate, dexamphetamine, 
lisdexamfetamine and amphetamine) and nonstimulants (atomoxetine, guanfacine and 
clonidine) 47. Stimulants that aim to increase extracellular levels of dopamine and 
norepinephrine by blocking their transporters and their reuptake into the presynaptic neurons 
have been proven to be effective with long-term benefits for ADHD. Non-stimulants are used 
as second-line pharmacological treatment. The non-pharmacotherapy for ADHD, namely 
behavior therapy includes parenting intervention, classroom intervention and cognitive 
behavioral therapy (CBT) 16. Behavior therapy is an alternative option when considering the 
safety and efficiency for young children. The multi-modal treatment with CBT as an adjunct 
to medication seemed to have the best improvement for patients 48. The vast majority of ADHD 
patients are on pharmacological treatments for a long time. A number of common side effects 
are observed from ADHD medication, such as loss of appetite, dry month, nausea, insomnia, 
cardiac problems etc. 2. Dietary intervention has been proposed to be another non-
pharmacological option that can ameliorate some symptoms of ADHD 49. A recent published 
twin-registry study in adults showed high fat, sugar, protein consumptions and unhealthy 
dietary pattern were positively correlated with ADHD symptoms, while fruits, vegetable 
consumptions and a healthy dietary pattern were negatively correlated with ADHD symptoms 
50. Restriction on artificial food colorants, artificial sweeteners, sugar and supplements with 
amino acids, fatty acids, vitamins, minerals have shown some beneficial effects, but only 
restricted food colorant diet and omega-3 supplementation had consistent effects and are 
effective in reducing ADHD symptoms 49, 51. A small randomized trial has proposed that early 
life probiotic supplementation reduced the risk for developing ADHD and Asperger syndrome 
later in childhood 52.  Furthermore, a newly published pilot study revealed an effect of probiotic 
on improving quality of life for young persons with ADHD 53. However, data from the studies 
are not sufficient to recommend diet intervention as a standard ADHD treatment, more 
knowledge is in great need. Therefore, more research and investigation is required to 
substantively ascertain the link between the gut flora and the central nervous system (CNS).  
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1.2 GUT-BRAIN AXIS 
GBA, also known as MGBA is the bidirectional signaling pathway between the gastrointestinal 
(GI) tract and the CNS. The signaling pathways in the axis is via the neural system (spinal cord, 
vagus nerve, enteric nerve), the immune system (immune cells and inflammatory mediators), 
the neuroendocrine system (HPA axis), gut microbiota and the derived metabolites (e.g. 
SCFAs, peptidoglycan, tryptophan and gamma-aminobutyric acid) that can pass the barrier 
paths (intestinal mucosal barrier and blood‑brain barrier (BBB)) 54. In the past two decades, the 
GBA is gaining more and more attention in fields of psychiatric, neurodevelopmental, and 
neurological disorders, regarding the biology, physiology and pathology 55, 56. 
1.2.1 Gut microbiota, synbiotics and antibiotics 
Microbiome was originally defined as “a characteristic microbial community occupying a 
reasonably well-defined habitat which has distinct physio-chemical properties. The term thus 
not only refers to the microorganisms involved but also encompasses their theatre of activity”. 
However, many current researchers have described the term microbiome simply as “the 
collective genomes of microorganisms inhabiting a particular environment and especially the 
human body”. Microbiota are ecological communities of microorganisms (bacteria, virus, 
fungi and archaea) and gut microbiota is the community that lives in the GI tract. It is one of 
the principal components in GBA. Gut bacteria have the great numbers and biodiversity, 90% 
of which are anaerobes. The gut microbiota is an ecosystem that is dynamic throughout the 
lifespan. Gut microbiota has become an important player for host physiology in both health 
and disease and for maintaining organismal homeostasis, which is of the utmost importance 56. 
Studies have highlighted the interactions between the gut bacterial microbiota and the brain, 
showing altered gut bacterial profiles in patients with depression, anxiety, ASD and 
schizophrenia 57-59. Regarding ADHD, there are only two studies that have revealed difference 
in the gut bacterial profiles from controls: one showing less abundance of Faecalibacterium in 
children with ADHD (n=51) and the abundance was negatively associated with symptom 
severity; the other one showing increased abundance of Bifidobacterium in adolescents and 
adults with ADHD (n=19) 60, 61. More supportive results from germ-free or antibiotic-treated 
animal models have indicated that the absence or depletion of gut bacterial microbiota affected 
the brain activities and behaviors (depression, anxiety, hyperactivity sociability and cognition), 
particularly in early life 8, 55, 62-65. Possible roles of gut microbiota on neural pathways and 
endocrine and immune mechanisms have been studied, including maturation and activation of 
microglia cells, oligodendrocyte differentiation, mitochondrial metabolism, synaptogenesis, 
permeability of the BBB, neurotransmitter metabolism, neurotrophy and neurogenesis 62-64, 66, 
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67. Animals administrated with specific bacterial strains showed changes in behaviors 68, 69. 
Although these behavioral and mechanistic studies are difficult to translate into humans, 
transferring fecal bacteria from autism, depression or schizophrenia patients to the germ-free 
or microbiota-deficient rodent intestine did induce behaviors resembling these disorders and 
influence biochemical modulations involved in the disorders 70-72. 
Synbiotics are dietary supplements with a combination of probiotics (generally, live beneficial 
bacteria that normally inhabit the human intestinal tract) and prebiotics (non-digestible fibres 
promoting the survival of beneficial bacteria in the intestinal tract) 73, 74.  These ingredients are 
generally regarded as safe, and have health benefits for the host by restoring the ecosystem of 
microbiota in the GI tract. Previous studies have revealed some positive effects from certain 
prebiotics or probiotics on stimulating the immune activities, regulating vitamin synthesis and 
modulating brain functions 75-78. Some open-label interventions with probiotics/prebiotics in 
pediatric autism patients reduced GI symptoms and psychiatric symptoms 79-81. Notably, a 
recent randomized controlled trial (RCT) in Finland showed that oral administration of the 
probiotic strain Lactobacillus rhamnosus GG during the first 6 months of life reduced the 
development and presence of ADHD and Asperger syndrome when at 13 years of age 52.  
Giving the same strain (Lactobacillus rhamnosus GG) to young persons with ADHD, improved 
the self-reported quality of life and changed cytokine levels in serum 53. 
Many other factors can have influence on gut microbiota composition (abundance and 
biodiversity) especially in early life, such as infection, use of antibiotic drugs, mode of birth 
delivery, environmental stressors. Among them, antibiotics generally can disrupt the bacterial 
homeostasis in the gut and intestinal barrier, which can open up for further opportunistic 
infections. To date, population-based registry studies in Denmark have recently reported that 
infections and antibiotic drug exposures before adulthood increased the risks for mental 
disorders, including ADHD and ASD 45, 82. However, other studies found no associations 
between the antibiotic exposure during the first two postnatal years for ASD or ADHD 83, 84. 
Further, a cohort study conducted in New Zealand reported that the first year antibiotic 
exposure associated with behavioral difficulties and mood symptoms 85. Although, results from 
current studies are a bit inconsistent, the possible associations between antibiotic drug exposure 
and psychiatric and neurodevelopmental disorders might not only reflect the link between the 
gut microbiota and brain, but also targeted infections or immune activation. 
 
8 
1.2.2 Immune activation, inflammatory mediators 
The immune system constitutes an important part of GBA, with the circulating immune activity 
mediators (e.g. cytokines, chemokines, acute-phase proteins, adhesion molecules) being the 
key molecules. They are small proteins or peptides secreted from immune cells (e.g. 
lymphocytes, macrophages, mast cells, microglia) and other cell types (e.g. fibroblasts, 
endothelial cells, adipocytes), which are important for the cell signaling in the immune system. 
There is a growing number of studies from both humoral and cellular pathways demonstrating 
a bidirectional immune-brain interactions in psychiatric disorders 56, 86, 87. The immune system 
is being recognized for its importance in neurodevelopment with specific interest in 
schizophrenia, ASD and ADHD 56, 87. Dysregulations of the immuno-inflammatory system 
have been implicated in mood disorders, schizophrenia and ASD, and have been proposed to 
be implicated also in e.g. ADHD 88-92. The prevalence of inflammation in depression, anxiety 
disorders and schizophrenia was 21-42% 93. Alterations in peripheral inflammatory marker 
levels have consistently been reported overrepresented in psychiatric disorders. The commonly 
studied markers in cohort studies include interleukins (e.g. interleukin (IL)-1β, IL-2 IL-6, IL-
10, IL-12, IL-13, IL-17, IL-23), chemokines (e.g. monocyte chemoattractant protein 1 (MCP1), 
Eotaxin1, growth-regulated oncogene α (GRO-α)), interferons (e.g. interferon (IFN)-γ), tumor 
necrosis factors (e.g. tumor necrosis factor α (TNFα)), growth factors (e.g. transforming growth 
factor β (TGF-β), vascular endothelial growth factor A (VEGF-A)), acute-phase proteins (e.g. 
C-reactive protein (CRP), serum amyloid A (SAA)), soluble cytokine receptors or receptor 
antagonists (e.g. sIL-2R, sTNFR and IL-1RA) , adhesion molecules (e.g. intercellular adhesion 
molecule 1(ICMA-1) and vascular cell adhesion protein 1 (VCAM-1)) and immunoglobulins 
(e.g. IgG, IgM) 87, 94, 95.  
Among them, IL-1β, IL-6 and CRP are the most commonly investigated peripheral 
inflammatory markers and most promising markers showing consistent results to predict 
clinical outcomes 93, 96. CRP is liver-derived acute phase protein that responds rapidly to 
infection, and clinically the level at between 2 to 10 mg/L are considered as metabolic 
inflammation states or noninfectious inflammatory conditions 97. IL-12 subunit p40 (IL-12/IL-
23p40) is a subunit shared with IL-23.  Its plasma level was found to be elevated in patients 
with schizophrenia and ASD 98, 99. In addition, IL-12/IL-23p40 was also reported to involve in 
the pathology in inflammatory bowel disease (IBD) and is a novel therapeutic target for the 
disease 100, 101. The marker associated with both brain and gut, which suggested its important 
roles in the GBA. ICMA-1 have been recognized in psychiatric disorders because of its role in 
neuroinflammation and BBB function and the soluble isoform was increased in major 
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depression, bipolar disorder, and dementia as well as ADHD in a small case-control study 95, 
102. ICAM-1 is expressed in endothelia cells and immune cells (leukocytes, microglial cells and 
astrocytes), which are involved in both the peripheral and CNS immune system. VCAM-1 is 
only expressed on endothelial cells and is located on large and small blood vessels when 
stimulated by cytokines 103. Both ICAM-1 and VCAM-1 are cell surface binding proteins that 
can mediate the immune-endothelial cell adhesion and signal transduction. They are commonly 
recognized as important biomarkers for inflammatory processes in cardiovascular diseases, 
particularly in atherosclerosis 103. Only a few small studies found significant difference at 
levels, showing higher soluble ICAM-1 (sICAM-1), IL-6 and IL-10 in children with ADHD 
102, 104, 105. Studies on immuno-inflammation is much less in ADHD than in schizophrenia, 
mood disorders and ASD, especially in the adult population 87, 106-108. The levels of IL-6 and 
TNF-α were correlated with hyperactivity/impulsivity scores in children and adolescents with 
obesity 109 and CRP levels correlated with child behavior checklist of attention problems 110. 
Identification of inflammation state as well as the immune activities in ADHD would have 
valuable implications in pathophysiology of the disorder. Future studies of the molecular and 
cellular processes for inflammatory biomarkers underlying the GBA should be encouraged. 
The emerging field of “immuno-psychiatry” will possibly lead to the discovery of more 
effective personalized treatment strategies.  
1.2.3 Short-chain fatty acids 
SCFAs are a group of fatty acids with less than six carbon atoms, which have been proposed 
to be one of the key messengers in the GBA 11. They are predominantly produced by anaerobic 
colonic microbiota when fermenting dietary fibres, such as beta-glucans and resistant starch, 
but are also naturally present or added as additives in food 111-115. The shorter members, with 
2-4 carbon atoms, acetic acid, propionic acid and butyric acid, are the common ones with great 
research interests 11. SCFAs are weak organic acids that can be taken up and utilized as energy 
source by colon cells. SCFAs are able to pass into the blood vessels in the wall of the intestine 
through either passive diffusion or active transportation via the monocarboxylate transporter 1 
(MCT1) or sodium-coupled MCT1, thereby enabling their systemic access and opportunity to 
reach the brain by passing the BBB 11, 113, 116. SCFAs, notably acetate, propionate and butyrate, 
exert central effects via binding to specific G-protein-coupled receptors, also called free fatty 
acid receptors (mainly GPR41/FFAR3, GPR43/FFAR2) 117, 118, which are widely expressed on 
a variety of cell types, including the intestinal epithelial cells, adipose cells, immune cells, 
pancreatic β cells, brain endothelial cells and neural cells in ganglia 117, 119. The metabolic and 
molecular pathways of SCFAs are complex. There are various studies on the different functions 
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of these molecules in both health and disease, including maintenance of gut function, immune 
regulation, metabolism homeostasis and associations with IBD, obesity, diabetes, autoimmune 
diseases, neurological disorders and psychiatric disorders113, 120, 121. 
Data from animal models have shown that SCFAs are implicated in broad physiological 
activities of the nervous system, which include the calcium-dependent neurotransmitter release, 
electrophysiology, neuroinflammation, microglial maturation and activation, as well as gap 
junction gating in the BBB 10, 66, 122, 123. Furthermore, butyrate was shown to elevate BDNF 
expression, to promote neurogenesis and neural proliferation in rodents and to facilitate long-
term memory consolidation 124-127. Emerging evidence shows that SCFAs, such as propionate 
and butyrate, play important roles in brain activities and behavioral development. An acute 
dose of butyrate enhanced learning and memory, increased sociability, and decreased 
depressive-like and perseverative behaviors in an ASD mouse model 128.  In contrast, 
administration of high-doses of butyrate or propionate induced reversible stress-like, anxiety-
like and autism-like behavior in rodents 113, 129, 130.  The different observations of SCFAs on 
behaviors may likely depend on the dose applied.  It is worth noting that physiologically 
circulating levels of SCFAs are relative low, in the μM range and the only detectable SCFA in 
cerebral spinal fluid (CSF) is acetate (36 µM) in human 111, 131. Importantly, in an in vitro 
model, propionate at as low as 1 µM can influence the BBB function 132, which further indicates 
that physiologically relevant SCFAs could be crucial in regulating brain activities. Lower fecal 
acetic acid, butyric acid and higher valeric acid levels were found in children with ASD and 
the lower levels were associated with less emotional problems in healthy children 133, 134. 
SCFAs are also detectable in human amniotic fluid (AF) 135. A few studies found live 
microbes/microbial DNA in human AF, placenta, meconium, as well as umbilical cord blood 
135-143. However, a recently published paper found no evidence for the existence of microbial 
DNA in placenta of healthy full-term pregnancies 144. Currently, there is no consensus of the 
existence of microbes in AF due to the limitation of contamination and cultivation. Normally, 
the exposure of SCFAs to fetus in utero is thought to originate primarily from the maternal gut-
produced SCFAs via the blood passing the placenta and possibly from amniotic microbiota 135. 
In rodents, maternal diet had impacts on gut microbiota, which further influenced the social 
behaviors and synaptic activity in the offspring 145. Maternal oral supplementation of SCFAs 
increased number of fetuses, reduced abortion rate 146, and ameliorated type 1 diabetes in 
offspring of a rat model via downregulation of inflammation 147. Subcutaneous injection of 
propionate into pregnant rat, or later to offspring induced more anxious and antisocial behaviors 
in female offspring 148. All these findings suggested that the fetus can be exposed to the SCFAs 
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produced by the maternal gut bacteria through systemic routes, and that this can influence the 
neurodevelopment in a very early time window.  
Anti-inflammatory actions of SCFAs are known to be exerted by modulating immune cell 
differentiation, chemotaxis, reactive oxygen species release and cytokine release 120. Butyrate 
elicited anti-inflammatory effects by inhibition of pro-inflammatory molecules IL-12, IL-1β, 
TNFα, nitric oxide production and upregulation of anti-inflammatory cytokine IL-10 
production 120. Moreover, SCFAs are important for modulating both intestinal barrier and brain 
barrier. SCFAs can stimulate mucus production and tight junction assembly that affect the 
intestinal mucosal and epithelial barrier 149, 150. A recent in vitro study showed that propionate 
has an anti-inflammatory role and protects BBB functions via several pathways 132. Some of 
the above functions of SCFAs are possibly mediated by their specific receptors 
(FFAR2/FFAR3). Other functions, in particularly for propionate and butyrate, are likely 
mediated through their histone deacetylase (HDAC) inhibitory role, which is important for 
epigenetic regulation of gene expression 124, 151-153.  
Taken together, SCFAs seem to be of great importance in GBA. It is worth exploring the roles 




























 “Behavior isn't something someone has. Rather, it emerges from the interaction of a 
person's biology, past experiences, and immediate context.” 





The overall aim of this thesis was to explore certain aspects of the GBA in neurodevelopment, 
with a focus on ADHD, and to explore a new adjuvant therapeutic strategy for ADHD. Study 
I was mainly focusing on early life exposure of antibiotics for developing ADHD and other 
psychiatric disorders later in childhood, while Study II, was designed to investigate the 
vascular immune activity in ADHD.  Studies III and IV aimed to study the effects of an 
intervention on the gut microbiota in regard to clinical outcomes, immune activity and 
microbiota metabolites. Study V investigated the effect of SCFAs on human neural progenitor 
cells in vitro model. 
The specific aims of each study were listed as follows: 
Study I: To investigate if exposure to antibiotics, prenatally and in the first 2 years of life, 
influences the risk for a wide spectrum of psychiatric disorder up to 18 years of age using 
Finnish nationwide registers. 
Study II: To explore levels of vascular inflammation in ADHD and their associations with 
psychiatric features in a case-control setting. 
Study III: To determine if Synbiotic 2000 composed of three anti-inflammatory lactic acid 
bacteria and four anti-inflammatory fibres has an effect on ADHD, comorbid autistic 
symptoms and daily functioning in patients with an ADHD diagnosis using a placebo-
controlled randomized trial. 
Study IV: To investigate the effects of Synbiotic 2000, a combination of dietary fibres and 
lactic acid bacteria, on the plasma levels of immune activity markers and SCFAs in children 
and adults with ADHD. 
Study V: To explore if SCFAs affect the growth of early stage neural cells, using human neural 























3 MATERIALS AND METHODS 
 
This section briefly describes the study populations and cell resource, as well as basic 
explanations of experimental and statistical methods used in the studies for the thesis. More 
details regarding materials, methodologies and statistics can be found in the Materials and 
Methods section of each individual study. 
 
3.1 STUDY POPULATIONS 
3.1.1 Finnish nation-wide registers (Study I) 
All live births (N=990,098) in Finland between 1996 and 2012 registered in the Drugs and 
Pregnancy Database (DPD) were included in Study I. The DPD is derived from the Medical 
Birth Register (MBR), the Register on Induced Abortions (supplemented by birth and death 
certificates, Cause-of-Death Register and maternity hospital records) and the Register of 
Congenital Malformations. The majority of the contents in MBR were well supported and 
validated in hospital record data. 
Information on exposure of antibiotic drug prescriptions were collected prenatally (mother 
during pregnancy) and postnatally (child at first 2 years of life) from the Finnish Register on 
Reimbursement Drugs (RRD), which registers all reimbursed drug purchases at pharmacies 
between 1996 and 2012. The DPD includes all RRD records of maternal purchases during 
pregnancy and the offspring purchases as well. 
The outcome of the study was the psychiatric disorders for the offspring, primary or secondary 
diagnoses from birth to 2014. Information was obtained from the Finnish Care Registers for 
Health Care according to the WHO ICD-10 system. Additional outcome was the prescription 
of psychotropic drugs for offspring, which was obtained from the RRD using the Anatomical 
Therapeutic Chemical classification system and included N05 (antipsychotics, anxiolytics, 
hypnotics and sedatives), N06A (antidepressants) and N06B (psychostimulants and 
nootropics).  
Demographic information on offspring birth year, sex, perinatal problems (prematurity and 
small birth size), number of fetuses, mode of delivery, maternal age at delivery, parity, the 
mother’s country of birth and marital status, and maternal smoking were available in the DPD.  
All the data was kept and obtained via our collaborator at the Finnish National Institute for 
Health and Welfare. The study was approved by the Regional Ethical Review Board in 
Stockholm (THL/1662/5.05.00/2015 and THL/1853/5.05.00/2016). 
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3.1.2 Randomized controlled trial (Study II, III, IV) 
Our group set up an RCT (ISRCTN57795429) for individuals with ADHD (named BAMBA) 
at three psychiatric out-patient clinics in Stockholm from January 2016. Participants were 
recruited until June 2018, also via local newspapers. Patients, who had a confirmed ADHD-
diagnosis with ICD-10 or DSM-V, were 5–55 years old, on stable pharmacological treatment 
(no change during the last 4 weeks), able to read Swedish, but not had an autism diagnosis, GI-
disorder diagnosis (except irritable bowel syndrome), celiac disease, diabetes and antibiotic use 
(during the last 6 weeks) were included and randomly allocated to interventions (N=248). The 
active invention, Synbiotic 2000 (Synbiotics AB, Sweden), was a composition of 4 × 1011 CFU 
per dose of three lactic acid bacteria Pediococcus pentosaceus 5–33:3/16:1 (Strain deposit 
number: LMG P20608), Lactobacillus casei ssp paracasei F19 (LMG P-17806), Lactobacillus 
plantarum 2362 (LMG P-20606), and 2.5 g of each of the fermentable fibers betaglucan, inulin, 
pectin and resistant starch. Previous RCTs with Synbiotic 2000 have shown anti-inflammatory 
and anti-infection effects in patients after surgery (liver transplantation, multiple trauma, 
pancreas resection) 154-156. Placebo was maltodextrin, an oligosaccharide without prebiotic 
effect. Each intervention lasted for nine weeks with assessments at baseline (the day before 
treatment start) and post-treatment (within 2 weeks after last treatment intake). A number of 
participants dropped out during the intervention in both placebo (N=21) and positive treatment 
(N=43) arms. 182 effective completers were included in the data analysis. Information on 
psychiatric symptoms and GI symptoms as well as biological samples (blood, urine and feces) 
from before and after intervention were collected.  
In parallel, healthy controls (N=61) fulfilling the same criteria, but without ADHD diagnosis 
were recruited as well. Information and biological samples were collected at one timepoint, 
and was applied to the Study II for the case-control design. 
The studies were approved by the Regional Ethical Review Board in Stockholm (2015/884-
31/1 and 2017/91-31,). 
 
3.2 IN VITRO EXPERIMENTATION 
3.2.1 Cell culture (Study V) 
The human neural progenitor cells (hNPCs) used in Study V were generated from the human 
embryonic stem cell line (HS980) kindly provided by Professor Outi Hovatta at Karolinska 
Institutet as follows. HS980 were cultured in NutriStem hESC XF medium on laminin-521 
(LN-521, 30 μg/ml) coated plate, in a way similar to the protocol by Rodin et al. 157. Following 
the previously described method by Falk, Koch, & Kesavan 158, HS980 cells were dissociated 
into single cells using TrypLE Select and plated on non-adhesive plastic in new medium of 
DMEM/F12 supplemented with 1% N2, SMAD inhibitors, SB-431542 and LDN-193189. 50% 
of the culture medium was replace with fresh medium every day until the 6-day-old floating 
aggregates were seeded into tissue culture plates coated with 0.002% poly-L-ornithine and 20 
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μg/ml murine laminin. About 2–3 days after plating, it started to form the neural rosette 
structures. On day 4 after plating, neural rosettes were manually picked up and transferred to a 
new coated well at high density in DMEM/F12 medium supplemented with 10 ng/ml FGF2, 
10 ng/ml EGF, 1% N2 and 0.1% B27. There, the hNPCs were generated and could be cultured 
to at least the 25th passage in our laboratory. 
Cultivation and in vitro experimentation of HS980 and hNPCs were approved by the Swedish 
ethical review board in Stockholm (2017/1079-31/1). 
3.2.2 IncuCyte live imaging 
Cells were seeded into 48-well plates and treated with SCFAs and incubated for 12 hr. 
Thereafter, 300 μl of fresh cell culture medium, SCFAs and 20 μg/ml propidium iodide (a 
common red-fluorescent nuclear dye used to stain apoptotic cells) were added into each well. 
The plate was placed into the IncuCyte ZOOM system incubator. Every second hour, four live 
images were taken from each well of the plate and the confluency percentage data and red 
staining count of each image were recorded at the same time. Data from the triplicates’ mean 
of the four images per well were treated as one biological replicate for each condition. Cell 
growth rate was model with the confluency data applying a nonlinear least square model, which 
was fitted to the data by finding the best coefficients. The maximum growth rate was calculated 
and reported for cell proliferation. Apoptosis rate from the red-stained cell count data was 
calculated as change in number of red cells over two hours.  
3.2.3 Immunofluorescence 
After exposure, cells were harvested inside each well of the plate. Immunofluorescence 
staining with pHH3 (phospho-histone H3, a marker for mitosis) was performed as follow: cells 
were washed twice with phosphate-buffered saline and fixed with 4% formaldehyde on ice for 
30 min. Cells were washed twice more with PBT buffer (PBS + 0.5% Tween-20) and blocked 
with PBTA buffer (PBS + 0.3% TritonX-100 + 0.1% bovine serum albumin  + 5% donkey 
serum) at 22°C for 40 min. Cells were incubated with pHH3 primary antibody in PBTA at 4℃ 
overnight, followed by washing twice with PBT and incubating with secondary antibody at 
22°C for 45 min. After staining with DAPI at 22°C for 5 min, cells were imaged by an 
automated high-content imaging system, Cell Observer. After loading the layout information 
of plate and setting parameters of the system, images were taken automatically. Automatic cell 
counting for all images was carried out by ImageJ, which recorded the total number of cells 
and intensity of the fluorescence of each cell. Percentage of pHH3 positive cells was calculated 
and reported (mean of triplicates per condition per plate) corresponding to a predefined 
intensity threshold for pHH3 positivity, which was done by a human analyst. 
3.2.4 Quantitative reverse transcriptase PCR 
Total RNA was extracted from the cells using using Direct-zol™ RNA MinpRrep Plus Kit 
according to the standard manufacturer's instructions. RNA concentration and purity 
(A260/A280) were measure by NanoDrop™ 2000 Spectrophotometers, with concentration at 
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50 ~ 120 ng/l and A260/A280 at 1.8 ~ 2.1 for all samples. cDNA was synthesized directly after 
RNA extraction using SuperScript® III First-Strand Synthesis System for quantitative reverse 
transcriptase PCR (qRT-PCR) according to the standard protocol for cDNA synthesis. qRT-
PCR was carried out in a QuantStudio™ 6 Flex Real-Time PCR system using SYBR Green kit 
following the standard settings. All reactions were run in triplicates. The relative mRNA gene 
expression was presented based on Ct value of the triplicates that was normalized by reference 
genes, β-actin (ACTB) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). 
 
3.3 IMMUNE ACTIVITY MARKER MEASUREMENTS 
Plasma levels of inflammatory cytokines, chemokines and acute phase proteins were measured 
using the Meso Scale Discovery (MSD) platform. It is a sandwich immunoassay technology 
that allows both pre-designed and custom-designed multiplex assays for the measurement of a 
combination of molecules in biological samples. The biotinylated capture antibody is coupled 
to a linker that specifically self-assemble to the unique spot in each well in the multiplex plate. 
The molecule of interest in the sample binds to the captured antibody-linker complex, and can 
be detected by another antibody conjugated with an electrochemiluminescent label of SULGO-
TAG that can bind to the molecule as well. The MSD instrument read the light signal emitted 
from the captured label, and the intensity corresponds to the quantity of the molecule in the 
sample. 
The self-designed inflammatory profile of 24 markers were measured with VPLEX, 3-spot, 7-
spot and 10-spot UPLEX assays in our lab according to the manufacturers. Four markers 
measured with VPLEX were included in Study II and III, and all 24 markers were investigated 
in Study IV. Five markers were excluded from Study IV because the signals were substantially 
(>25 % total measures) below the lower limit of detection. All samples were measured in five 
96-well plates for each assay. The median (range) of intra- and inter-assay coefficients of 
variation (CVs) were below 2.5 (1.1%- 5.3%) and 9.9% (4.6%-16.9%), respectively. 
 
3.4 SHORT-CHAIN FATTY ACID MEASUREMENTS 
The plasma SCFA profile included nine fatty acids (formic, acetic, propionic, butyric, 
isobutyric, succinic, valeric, isovaleric and caproic acid) and were measured by liquid 
chromatography–mass spectrometry (LC-MS) according to a protocol published by Han J et 
al. 2015 with some modifications, at the Department of Biology and Biological Engineering, 
Chalmers University of Technology, Gothenburg 159. All samples were measured in two rounds 
(four months in between), being six 96-well plates for the first round and five 96-well plates 
for the second round. Twenty-two samples were selected to run in both rounds in order to 
control for batch effects. The levels of five SCFAs (formic, acetic, propionic, succinic and 
isovaleric acid) showed high consistency between the two rounds. Therefore, data from these 
five SCFAs were included in the analysis. The median (range) of intra-assay CV was 9% (5%-
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11%) for the same two quality controls run on each plate. The inter-assay variation was 
controlled by normalization with the two quality controls. All plasma samples had undergone 
the same sample preparation steps and two freeze/thaw cycles for the analysis.  
 
3.5 STATISTICAL ANALYSIS  
This section covers main statistical methods used in the five studies, including the Cox 
proportional hazards model used in Study I, correlation and linear regression used in Study II, 
III and IV, analysis of covariance (ANCOVA) used in Study III and IV as well as corrections 
for multiple testing in Study II, IV and V. A number of commonly used simple tests (Study 
II-V), including t-tests, Mann–Whitney U test and analysis of variance (ANOVA) will not be 
further discussed in the thesis. All data analysis were performed in R programming software. 
3.5.1 Cox proportional hazards model 
The Cox proportional hazards model is an advanced regression model that is commonly used 
in medical research, to study the association between a specific event happening (e.g. diagnosis, 
death) at a time point and one or more predictor variable(s) (e.g. smoking, infection). The 
model evaluates the effect of the predictors for outcome over time and simultaneously reports 
the hazard rate. In study design, the predictors always have more than one conditions, and one 
of them was selected as the reference group. Hazard ratio (HR) is the ratio of the hazard rates 
corresponding to the reference group. 
In medical research, there are many situations or factors, also known as covariates, which can 
potentially affect patient prognosis. Here, the Cox model allows us to analyze survival or 
outcome with respect to several factors simultaneously and provides the effect size for each 
factor at the same time. 
In Study I, we studied the effects of predictor variables, exposed or not exposed to antibiotic 
drugs in early life, on the development of psychiatric disorders in childhood. For each 
individual born between 1996 and 2012 and followed up until 2014, the onset time of a 
psychiatric disorder is different, therefore we selected Cox model to study the hazard ratios 
representing instantaneous risk with less bias on the endpoints of the study.  
3.5.2 Correlation 
Correlation, also known as dependence is a statistical method mainly to study to what extent 
two quantitative variables are related. The most common Pearson correlation test is applied to 
assess the linear relationship between normally distributed variables. There are also more 
robust methods for non-normally distributed data, such as Spearman's rank correlation test and 
Kendall's rank correlation test, to measure the effect as one variable increases, while the other 
variable tends to increase or decrease. A high correlation coefficient indicates that the two 
variables have a strong relationship with each other. 
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In Study II and IV, the relationship between two marker levels as well as between marker 
levels and clinical symptom scores were assessed by Spearman's rank correlation. The 
coefficients (r) and p values were reported in the results. 
3.5.3 Classical linear modeling 
Linear regression is a statistical model to study the relationship between an outcome variable 
(dependent variable) and one or more predictors (independent variables). The parameters of a 
model are estimated from the given set of data. To fit a linear model, it is possible to increase 
the likelihood by adding parameters, but may result in overfitting. Least squares approach is 
often used to fit a linear regression models. There are also other ways for model fitting, such 
as Akaike information criterion (AIC). It is a useful criterion for model selection, which attempt 
to resolve the overfitting and underfitting problems by estimating the amount of information 
lost by a model. Thereby, the values from AIC estimate the relative quality of statistical models, 
and the lowest values are preferred for a fitted model. 
In Study II, we modelled the relationship between the inflammatory marker levels and the 
clinical variables collected, we performed stepwise backward elimination regression and used 
AIC to select the best model with certain predictive variables for each marker.  
ANCOVA, as the name indicates, is an extended statistical model of ANOVA, which 
introduces regression into the model. It is a general linear model to evaluate whether the means 
of a dependent variable are different among several independent groups within a categorical 
variable (e.g. treatment), meanwhile statistically controlling for the effects of other variables, 
known as covariates that are not of primary interest but have possible influence on a dependent 
variable. We always interpret the model as the difference between groups if it is explained only 
by independent variable, since the model has adjusted for the variance explained by the 
covariates. 
In Study III and IV, the treatment effect between placebo and Synbiotic 2000 on symptoms, 
immune marker levels and SCFA levels were analyzed by ANCOVA, adjusted by age, sex and 
baseline measurements. Statistically, for pretest-posttest control group design, the treatment 
effects can be tested by either using (1) ANOVA with the change from baseline (post-treatment 
– pre-treatment) or (2) ANCOVA with the post-treatment timepoint as outcome and pre-
treatment timepoint as covariate. For Study III and IV, ANCOVA has been chosen based on 
its unbiasedness and increase in power in randomized studies compared to the power of the 
ANOVA with change 160. We reported the 95% and/or 99% confidence interval (CI) instead of 
p value, which is more informative especially for clinically relevant studies. A p-value gives 
information on if the null hypothesis should be rejected or not. The rejection of the null 
hypothesis can either be true (there is actually no difference between the groups) or false (there 
is a difference between the groups, but it could not be detected due to small effect sizes, large 
within-population variation or too small sample size). However, a CI reports the significance 




3.5.4 Correction for multiple testing 
Multiple correction is a statistical procedure used to control multiple testing problems, which 
happen when a statistical analysis involves multiple simultaneous tests of the same dataset or 
dependent datasets and each of the tests has a potential to produce a "discovery". Bonferroni 
correction is one of commonly used methods for correction for multiple testing in order to not 
obtaining false positive results. Bonferroni correction compensates the hypothesis testing by 
setting the desired α level to the former α level divided by the number of tests performed. Thus, 
Bonferroni correction offers a great protection against the type I error (false positive), but is 
often seen as overprotective and lacks power 162, 163 . The false discovery rate (FDR) is another, 
less stringent, method for correction and focuses on the proportion of false positives 164. In 
Study II, we used Bonferroni correction for the four markers investigated in the study by the 
α level at 0.025 (2 independent tests), because the four markers were highly correlated into two 
groups. In Study IV, we corrected multiple testing of nineteen markers or five SCFAs with 
FDR and Bonferroni (ANCOVA for treatment effect with α level at 0.01) methods. In Study 
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4 RESULTS AND DISCUSSION 
 
This section summarizes the main findings and provides a brief discussion of the studies 
included in the thesis. More details for each study can be found in the end of the thesis, which 
lists individual full-length paper or manuscript. 
  
4.1 STUDY I  
Antibiotic exposure and childhood psychiatric disorders 
Previous studies have reported that certain infections or anti-infective drug exposures were 
associated with increased risks for psychiatric disorders, such as psychotic disorders and 
affective disorders 45, 82. Moreover, peripheral immune activation is common in children with 
psychiatric disorders and recognized as an important factor in neurodevelopment 56, 87. Early 
life, especially the prenatal period is an important time window for neurodevelopment. There 
are a few cohort studies of effects of prenatal exposure to antibiotic drugs on psychiatric 
disorders, but without considering potential confounders, like family factors and 
socioeconomic factors. The hypothesis of this study was that antibiotic drug exposure during 
the fetal period and the first two postnatal years is associated with risks for later development 
of psychiatric disorders in children. 
4.1.1 Results  
In this cohort study, we used Finnish nationwide registers that included 1 million births to 
investigate the associations between exposure to antibiotics in utero and the first two years after 
birth and the risk for a group of childhood-onset psychiatric disorders. We found that antibiotic 
exposure during pregnancy or in the first two years after birth associated with modestly 
elevated risks for developing Mood disorders (ICD-10, F20–39, F92 ), Anxiety disorders (F40–
43, F93), Non-organic sleeping disorders (F51), ADHD and Conduct disorders (F90–F91) and 
Other behavioral and emotional disorders (F98) (Figure 1). These findings were also supported 
by the results from purchases of psychotropic drugs (N05: antipsychotics, anxiolytics, 
hypnotics and sedatives; N06A: antidepressants; N06B: psychostimulants and nootropics) to 
offspring (Figure 1). A dose-dependent effect was found with the number of antibiotic 
purchases during pregnancy and any offspring psychiatric diagnosis. Moreover, antibiotic drug 
purchase by mother during pregnancy had a higher risk than purchase three months before or 
three months after pregnancy for any psychiatric diagnosis in the offspring. Sibling pair 
analysis suggested that the effects detected were not fully explained by familial confounding. 
Moreover, the increased risk of offspring psychiatric disorder after prenatal exposure did not 
change after adjusting for maternal infection during pregnancy, which implied an antibiotic 
effect on psychiatric disorders independent of maternal infection. Stratification analysis with 
the type of antibiotics (airway antibiotics, urinary tract antibiotics and combined) showed no 
 
24 
clear difference in either prenatal or postnatal exposure, but it suggested that the broad-
spectrum antibiotics had a slightly higher risk for psychiatric disorders than narrow spectrum 
antibiotics. 
 
Figure 1. Overview of adjusted Cox Hazard Ratios for (i) psychiatric diagnoses (ICD-10 F 
diagnoses), and (ii) psychotropic medication, in relation to exposure to any antibiotic drug 
prenatally (trimester 1–3) or in the first 2 years of life, among 990,098 births (1996–2012). 
Figure from Lavebtratt C, Yang LL et al., 2019, Translational Psychiatry. 
 
4.1.2 Discussion  
This was a large longitudinal study (1996-2014) with 1 million participants and detected 
modest risks of early antibiotic exposure on offspring psychiatric diagnosis. Some previous 
nation-wide register studies on infection or antibiotic drugs exposures found increased risk for 
later ADHD, but some did not. Our study found that antibiotic exposure increased risks for 
ADHD. A dose-dependent effect of antibiotic purchase during pregnancy, and the higher effect 
size of the association with maternal antibiotic use during pregnancy compared to outside 
pregnancy, supported the vulnerability to antibiotic drug exposure in fetal period. The 
associations between antibiotic drug exposure and later psychiatric disorders might reflect 
direct effects of the targeted infections or antibiotic-induced bacterial dysbiosis that can further 
facilitate the downstream opportunistic infections and influence GBA signaling. A number of 
confounding factors, including maternal parameters, and birth-related parameters were 
adjusted for in the model, but we lack the genetic and environmental factors from the paternal 
side. The associations observed were modest, with the strongest being with sleeping disorder 
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(HR: 1.09-1.40), but, notably, there was no association with autism. This may partially be 
explained by the final sample size for each psychiatric disorder. However, the proportion of 
complete cohort for each disorder was not exactly in line with the onset age. All participants 
were followed up until 2014, with age 2-18 years. We did not control for the effects of antibiotic 
drug use after the first 2 years. The validity of psychiatric diagnoses, other than autism, in the 
registries used has not been reported and the magnitudes of the associations between diagnoses 
are considerably overlapping. This is an association study of epidemiological design that 
cannot infer causality. 
 
4.2 STUDY II 
Pro-inflammatory mediators in children and adults with ADHD 
Altered levels of inflammatory markers are gradually being discovered in psychiatric disorders, 
like ASD, schizophrenia and mood disorders 87, 94. However, there were not many studies on 
ADHD, especially among adults. Neurobiologically, ADHD as a neurodevelopmental disorder 
is quite similar to ASD and the comorbidity of each other is 15-25% for ADHD and 40-70% 
for ASD, respectively 19. Patients with ADHD often have problems on emotion regulation and 
GI disturbance that is closely associated with gut microbiota and immune activation. Acute 
phase protein, CRP and SAA are commonly investigated inflammatory marker in psychiatry. 
Adhesion molecules sICAM-1 and sVCAM-1 play important roles in endothelial function that 
facilitates the inflammation responses. These four markers share the same role in vascular 
inflammation and related cardiovascular diseases. We hypothesized that CRP, SAA, sICAM-
1, sVCAM-1 levels would be elevated in ADHD compared to controls and that higher levels 
would associate with severity of ADHD symptoms, functioning and medication with 
stimulants. Further, we hypothesized that the ADHD patients would manifest more GI 
symptoms and autistic traits, which would associate with elevated levels of the inflammatory 
markers. 
4.2.1 Results 
In this study, we measured the plasma levels of a panel of four markers in both ADHD and 
healthy controls. Levels of pro-inflammatory sICAM-1 and sVCAM-1 were significantly 
higher in ADHD patients than in healthy controls, also after adjusted for sex and age (Figure 
2). These four markers were highly correlated with each other. As expected, more comorbid 
autism symptoms and GI symptoms were found in ADHD than in controls. Among children 
with ADHD, those with ADHD medication had higher levels of sICAM-1 and sVCAM-1 than 
those without. The differences were significant for almost all types of ADHD drugs, especially 
for those children who were currently on medication. CRP levels were positively associated 
with GI symptoms and emotional regulation problems, and sICAM-1 were positively 
correlated with autistic symptoms in adults with ADHD. However, the associations were not 




Figure 2. Levels of CRP, SAA, sICAM-1 and sVCAM-1 in patients with ADHD and healthy 
controls. Figure from Yang LL et al., 2020, European Neuropsychopharmacology, in press. 
 
4.2.2 Discussion 
This was a case-control study that investigated four inflammatory mediators and their 
associations with ADHD medication, psychiatry symptoms and comorbid traits in children and 
adults ADHD. There is a lack of published studies on immune activity markers in adults with 
ADHD. Previous reports on cardiometabolic risk for ADHD suggested vascular inflammation 
in the disorder 165. Higher sICAM-1 levels as well as other inflammatory markers (e.g. IL-6, 
IL-10) were found in ADHD, which supported immune activation in ADHD 102, 104. Our study 
found significant higher levels of sICAM-1 and sVCAM-1 in ADHD, which indicated vascular 
inflammation in ADHD. Moreover, a common side effect of ADHD medication is increased 
heart rate and blood pressure, and sICAM-1 and sVCAM-1 are associated with hypertension 
and atherosclerosis. The higher levels of sICAM-1 and sVCAM-1 found in children with 
ADHD medication in our study implied a possible cardiovascular risk later for the group of 
patients. Both ICAM-1 and VCAM-1 are closely related BBB permeability, which is an 
important guard for neuroinflammation166, 167. The higher levels of sICAM-1 correlated with 
more autism symptoms in adult patients of our study. 
In the study, we analyzed four markers at a time with the pre-designed VPLEX, which is a 
robust assay with >99% specificity, high sensitivity and no cross-reactivity. For statistical 
analysis, we corrected for two independent tests for the four markers, because of the high 
correlations of sICAM-1/sVCAM-1 and CRP/SAA. At the same time, we also controlled for 
the potential co-variables (age, sex, body mass index (BMI) and ADHD medication) when 
analyzing the data. However, there were some limitations for the study. Firstly, the sample size 
of children was small (n=53) in this study. Secondly, only four children controls were recruited 
and the controls for adults consisted of both family members and unrelated people without 
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ADHD diagnosis. There was thus a certain bias regarding the genetics and environment for the 
two control subgroups, however we did not find any difference in marker levels between them. 
Thirdly, the BMI was not available for children. Fourthly, it was a study focus only on 
peripheral inflammation, not considering neuroinflammation. Replications with larger sample 
size will be necessary.  
 
4.3 STUDY III 
Effects of Synbiotic 2000 on clinical outcomes in ADHD 
In Study II, we have shown that GI symptoms were overrepresented in patients with ADHD 
and increased levels of vascular inflammation were in adults associated with more severe 
symptoms. Other studies also showed that patients who had more psychiatric symptoms, in 
parallel had more GI symptoms 168, 169. Growing evidence exists that the gut microbiota, a main 
component of GBA, influences the gut-brain interactions. Gut microbiota has shown to 
influence the systemic immune activities, permeability of the BBB, maturation and activation 
of microglia cells, synaptogenesis and motor control 56. Altered gut microbiota has been 
reported in patients with ADHD. Oral administration of certain bacteria (L. rhamnosus GG) 
the first 6 months of life reduced risk for ADHD and a few RCTs of prebiotics or probiotics 
suggested some positive effects on improving psychiatric symptoms 52, 61, 79, 170. Dietary 
supplementations, such as prebiotics/probiotics/synbiotic and omega-3 fatty acids have been 
proposed as possible options as adjuvant treatments to ameliorate ADHD symptoms. However, 
there is no randomized placebo-controlled trials in patients with ADHD. Our hypothesis was 
that Synbiotic 2000, a combination with three anti-inflammatory lactic acid bacteria and four 
anti-inflammatory fibres would reduce psychiatric symptoms and improve daily functioning.  
4.3.1 Results 
In this RCT, a total number of 182 ADHD patients completed a 9-week intervention with either 
placebo or Synbiotic 2000, which was combination of prebiotic (fibres) and probiotic (lactic 
acid bacteria) content (Figure 3). After the interventions, total ADHD symptoms and 
inattention or hyperactivity-impulsivity symptoms were significantly reduced for all 
participants regardless of treatment types. The reduction was similar in placebo and Synbiotic 
2000 and not different between the two groups. Likewise, there was no difference between 
Synbiotic 2000 and placebo on changing daily functioning. For autism symptoms, Synbiotic 
2000 treatment significantly reduced the restricted, repetitive and stereotyped behaviors as 
compared to placebo. The effect was pronounced for children with elevated inflammation 
levels (sVCAM-1) in plasma and for children currently on ADHD drugs such that also total 
autism scores was improved. Among adults, Synbiotic 2000 treatment resulted in better effects 
than placebo on emotion regulation in difficulties in engaging goal-directed behavior. This was 
also pronounced in those with higher sVCAM-1 levels such that function in four subdomains 
(difficulties in engaging goal-directed behavior, lack of emotional clarity, limited access to 
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effective emotion regulation strategies and nonacceptance of emotional responses) were 
improved.   
 
Figure 3. Flow chart of randomized controlled trail. Figure form Skott E*, Yang LL* et al., 
2020, Brain, Behavior, and Immunity. 
 
4.3.2 Discussion 
This is the first completed placebo-controlled RCT exploring the effects of a synbiotic on 
psychiatric symptoms and functioning in ADHD. Previous studies, mainly open-label design, 
have shown some positive effects of prebiotics and probiotics on autism, a common 
comorbidity with ADHD 81. In our study, we did not find any effect of Synbiotic 2000 on 
ADHD symptoms, but a significant effect on restricted, repetitive and stereotyped behavior of 
autism in children with ADHD.  Altered gut microbiota and peripheral immune activities have 
been found in individuals with ADHD 60, 61 102, 104, 105 and the interactions between the 
microbiota, immune and nervous systems are becoming important for psychiatric disorders 56.  
Our ADHD patients manifested elevated sVCAM-1 levels at baseline (Study II) and among 
the child patients with higher sVCAM-1 levels at baseline, an effect of Synbiotic 2000 on total 
autism symptoms and on the restricted, repetitive and stereotyped behaviors was observed. 
Likewise, for emotion dysregulation in adults with ADHD, we found that Synbiotic 2000 
improved difficulties in engaging in goal-directed behavior and among those with elevated 
sVCAM-1 levels at baseline there were effects both on total scale and on four out of five 
subdomains. These findings may reflect anti-inflammatory properties of Synbiotic 2000. 
The design of the study is a double-blind and placebo-controlled trial that reduced or eliminated 
certain experimental biases. The total sample size of the trial was large and the intervention 
time was long in the context of probiotic or prebiotic interventions in neuropsychiatric 
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disorders. The baseline clinical characteristics were similar the completers in the placebo and 
Synbiotic 2000 groups. In this study, we did not find significantly better synbiotic effects on 
the main primary outcomes of ADHD, but indeed for subdiagnostic autism traits and emotion 
regulation. A placebo effect reducing ADHD symptoms was observed and this was similar to 
that of Synbiotic 2000 effect. Placebo effects are however common in RCTs in psychiatry. In 
the analysis, we controlled for age and sex and stratified by an inflammation marker and ADHD 
medication. However, we did not control for drugs that have been reported to affect the gut 
microbiota, which may consequently influence the outcomes of Synbiotic 2000. Dietary 
variables, such as nutrients and dietary patterns, which recently were reported to be associated 
with ADHD symptoms in adulthood 50, are also important to consider. Unfortunately, we only 
had information at the times before and after treatment, which showed no changes over time 
except for beta-carotene. Our suggestive findings are preliminary and need to be confirmed 
using larger cohorts.  
 
4.4 STUDY IV  
Effects of Synbiotic 2000 on immune activity markers and SCFAs 
The effects of Synbiotic 2000 that we found on autism symptoms and emotion dysregulation 
in Study III, may act through lowering the inflammatory state in ADHD patients. SCFAs are 
fatty acids with less than six carbons, and they have been proposed to be important players or 
mediators in the bidirectional GBA. They are predominantly produced from dietary fibres by 
anaerobic microbiota in the gut, but they can pass the intestinal barrier, go into the blood 
circulation and reach the entire body. Some SCFAs have in in vitro studies been reported to 
have anti-inflammatory effects 120. We hypothesized that Synbiotic 2000 would influence 
plasma levels of inflammatory markers and SCFAs and that there would be associations 
between immune activity markers and SCFAs. 
4.4.1 Results 
Adult ADHD patients had a higher inflammation state than healthy controls at baseline, with 
elevated plasma levels of pro-inflammatory sICAM-1 and sVCAM-1 and reduced anti-
inflammatory IL-10 levels. Meanwhile, lower baseline plasma levels of formic acid and 
propionic acid were found in adults with ADHD. Synbiotic 2000, compared to placebo, 
reduced the levels of IL-12/IL-23p40 in children on ADHD medication and suggestively 
increased the levels of propionic acid in child patients. IL-10 levels negatively correlated with 
formic acid and acetic acid levels at baseline in both children and adults with ADHD. Further, 
at baseline sVCAM-1 negatively correlated with acetic acid and propionic acid, and sICAM-1 
with acetic acid in children with ADHD, while sVCAM-1 negatively correlated with formic 





With the same RCT as Study III, we explored the effects of Synbiotic 2000 on plasma immune 
activity markers and SCFAs. Results from Study III, showed that Synbiotic 2000 effects were 
more detectable in higher inflammatory state. In this study, we detected a higher inflammatory 
state in adult ADHD by increased pro-inflammatory sICAM-1 and sVCAM-1, and decreased 
anti-inflammatory IL-10 levels at baseline. However, we only found a significant effect of 
Synbiotic 2000 on IL-12/IL-23p40 level in children on ADHD medication, who had elevated 
vascular inflammation as reported in Study II. IL-12/IL-23p40 is a pro-inflammatory cytokine 
involved in the pathology of IBD 101 and has been reported to be increased in CSF from 
schizophrenia patients 98. On the other hand, the ingredients of Synbiotic 2000 include four 
fibres, which are a major source of SCFAs. The production of gut SCFAs are dependent not 
only on bacterial species but also on substrates. Anti-inflammatory and immune-modulatory 
roles of SCFAs were reported in previous studies 171. Here, the adult ADHD patients had lower 
formic acid and propionic acid levels at baseline. Although, there was only a suggestive 
Synbiotic 2000-specific treatment effect on SCFA levels, correlations between 
formic/acetic/propionic acid and sICAM-1/sVCAM-1/IL-10 were found at baseline. This 
suggested immune-SCFA interactions or GBA signaling in ADHD. Notably, the correlations 
were not seen neither for controls nor after Synbiotic 2000 treatment. 
In this study, we measured 24 immune activity markers in plasma with four independent assays 
(VPLEX, 3-spot, 7-spot and 10-spot UPLEX) from MSD. The VPLEX assay is a robust pre-
designed panel from MSD that measures 4 vascular inflammation markers (CRP, SAA, 
sICAM-1, sVCAM-1). The assay has been validated critically for sensitivity, specificity, 
accuracy, and precision. The other 20 markers were custom-designed and measured with three 
UPLEX assays and MSD platform have carefully controlled for cross-reactivity between 
markers. All the assays had generated standard curves with correlation coefficients >0.99. 19 
immune activity markers and 5 SCFAs had detectable values with acceptable precision and 
were included in the data analysis. In the analysis, we corrected for multiple testing using FDR. 
However, for the treatment effects, we adjusted for 5 independent tests through Bonferroni and 
reported 95% CI and 99% CI from ANCOVA models, to simplify result visualization. The 
most interesting findings were the correlations between the plasma immune activity markers 
and SCFAs, which were found to be altered in ADHD patients compared to healthy controls. 
Associations between SCFAs and membrane-bound endothelial adhesion molecules are still 
unknown. The small control sample size (n=4) made it impossible to detect any case-control 
difference for children. Replication in larger cohort is warranted. 
 
4.5 STUDY V 
Effects of SCFAs on neurodevelopment with in vitro model 
SCFAs derived from gut microbiota are found in the CSF and the AF 131, 135. SCFAs regulate 
several aspects of the neural system, e.g. neurotransmitter synthesis and release, microglia 
activation, growth of neurospheres and differentiation of embryonic stem cells 10, 152, 172. 
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Prenatal exposure to propionate revealed associations with later development of ASD, in both 
animal models and cell lines 113. Our hypothesis was that SCFAs would influence proliferation 
and apoptosis of hNPCs.  
4.5.1 Results 
In this study, early stage hNPCs generated from Human embryonic stem cell line HS980 were 
exposed to three main SCFAs, acetate, propionate and butyrate at different levels (Figure 4). 
We found that SCFAs at high doses (mM) had obvious toxic effects on hNPCs. However, at 
low doses (µM) that were close to physiological levels in human body fluids, the proliferation 
of hNPCs was increased and the apoptosis was not affected. A dose-dependent pattern was 
seen for all three SCFAs on proliferation (Figure 5). Furthermore, we found that low-dose 
SCFAs regulated the expression of genes involved in cell cycle, apoptosis and neurogenesis.  
 
Figure 4. Workflow for the (A) generation and (B) short-chain fatty acid (SCFA) exposure of 





Figure 5. Maximum proliferation rate estimated from the growth curves for SCFA treatments 
on human neural progenitor cells monitored using IncuCyte live imaging. Figure from Yang 
LL et al., 2019, Journal of Neurochemistry. 
 
4.5.2 Discussion 
To our current knowledge, this is the first in vitro study that explored the effects on hNPCs by 
SCFAs at physiologically relevant levels. The three SCFAs, acetate, propionate and butyrate 
that we have examined are among the most common and abundant ones, and propionate and 
butyrate seemed to have the stronger effects than acetate on hNPCs. SCFAs are present in AF 
and are thought to be primarily from maternal gut microbiota. Our hNPCs are early neural cells 
generated from a human embryonic stem cell line, which to certain degree probably mimics 
cells starting to appear in utero during the fourth week. Our findings of SCFAs stimulating the 
proliferation of hNPCs might reflect a putative ‘maternal gut-fetal brain-axis’. Furthermore, 
the pronounced association between prenatal antibiotic exposure and risk for developing 
ADHD found in Study I could possibly in part be explained by the ‘maternal gut-fetal brain-
axis’. The theory could be that antibiotic use during pregnancy affect maternal gut microbiota 
and SCFA production, which in turn influences the fetal neurodevelopment. Obviously, more 
studies are needed to test this speculation. 
In this study, the relative concentrations of the three SCFAs were designed according to 
physiological levels, but we did not investigate the exposures of the combination of the three. 
It is unknown whether the combination would have synergistic effects or toxic/acidic effects 
for the cells. SCFA effects are remarkably tissue and dose specific. The exposure time of 
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SCFAs in our study was 24 h and 48 h due to the technical limit for cultivation of the cells. 
Long-term effects can be addressed by exposures to not only hNPCs but also later stage neurons 
and 3D-organoids for longer time. Since SCFAs are molecules with multiple functions, e.g. 
FFAR2/3 activation, acidification, and HDAC inhibition, etc., more studies about the 






































“The road to health is paved with good intestines!” 




5 CONCLUSIONS AND FUTURE PERSPECTIVES 
 
5.1 CONCLUSIONS  
This section lists a brief summary of conclusions for each study and ends with a short 
concluding remark.   
Study I: Early life exposure to antibiotic drugs modestly increased the risk for developing a 
broad spectrum of psychiatric disorders (e.g. ADHD) later in childhood, which might reflect 
direct effects of the antibiotic-targeted infections, as well as indirect effects from antibiotic-
induced alteration of microbiota or a perturbed barrier. This may lead to downstream 
opportunistic infections and modified GBA signaling. This study is of value for public health, 
given the high frequency of early-life antibiotic drug use and the high prevalence of 
psychopathology in childhood and adolescence.  
Study II: Plasma sICAM-1 and sVCAM-1 levels were higher in patients with ADHD than in 
healthy controls, indicating vascular inflammation or endothelia dysfunction in ADHD. It 
would be of interest to examine the vascular biology both as it pertains to ADHD and current 
medications. Pro-inflammatory markers levels were related to current ADHD medication in 
children and certain comorbid autistic symptoms and difficulties in emotion regulation in 
adults. This may have diagnostic and therapeutic implications. 
Study III: Synbiotic 2000, as compared to placebo, did not have an effect on overall ADHD 
symptoms but it had beneficial effects on ADHD patients on reducing the restricted, repetitive 
and stereotyped behaviors in children and difficulties in regulating goal-directed behaviors in 
adults. In those with sVCAM-1 levels above the median these beneficial effects were found 
also on autism traits in general among children as well as on four of five domains of emotion 
dysregulation in adults. Currently, there is no effective pharmacological treatment specific for 
core autistic symptoms. If safe and easy dietary supplements, such as synbiotics could help to 
ameliorate symptoms or improve functioning in persons with ADHD or ASD, that would be 
beneficial for many patients. It would be of interest to further explore synbiotic treatment either 
during antibiotic treatment and/or for longer periods in ADHD patients. 
Study IV: Synbiotic 2000, as compared to placebo, significantly reduced the pro-inflammatory 
IL-12/IL-23p40 levels in children with ADHD on ADHD medication, suggestively reduced 
sICAM-1 levels, and suggestively increased propionic acid levels in children with ADHD. 
Baseline levels of immune markers (sICAM-1, sVCAM-1 and IL-10) and SCFAs (formic acid 
and acetic acid) in adult ADHD patients were different from those in healthy adults, indicating 
a higher inflammation level in patients. These immune marker levels were correlated with 
formic acid, acetic acid or propionic acid levels at baseline. The clinical effects of Synbiotic 
2000 observed in Study III may be through restoring enteric metabolites, in turn alleviating 
inflammation. The study proposes possible underlying mechanisms for the Synbiotic 2000 
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effects in individuals with ADHD, which warrants further exploration of immune activity and 
gut bacterial metabolites in ADHD. 
Study V: SCFAs, at human physiological levels, increased the proliferation and mitosis but 
did not affect apoptosis of human early neural progenitor cells. These findings lead to the 
proposal that may be a role for dietary and enteric SCFAs in early neurodevelopment. 
Considering the prenatal antibiotic drug exposure findings from Study I,  these effects of 
SCFAs on hNPCs suggest that maternal SCFAs/gut microbiota may have a role in fetal brain 
development via a putative ‘maternal gut-fetal brain-axis’ in health and disease. 
The emerging understanding of the communications between gut and brain in ADHD adds to 
the classical pathophysiological theories focusing only on the brain. Expanding the studies into 
immune activation and inflammation, may help to discover early biomarkers of the disorder. 
Interests in diet, gut microbiota and derived metabolites will open the mind for possible 
prenatal risk factors and novel therapies without adverse effects. More studies on the 
underlying mechanisms of GBA and components in ADHD are in great need. 
To summarize, the studies included in this thesis provide support for a putative role of immune 
activation and the GBA, and may in the future lead to the identification of therapeutic targets 
for certain individuals with ADHD (Figure 6).  
 
 




5.2 FUTURE PERSPECTIVES  
The importance of the GBA is increasing in neuropsychiatry and neurology. Yet, there is 
overall less focus on ADHD when compared to other psychiatric disorders such as ASD. The 
results presented in this thesis needs to be replicated, and several questions related to GBA in 
ADHD remain to be answered in the future.  
As it was suggested in Study II, endothelial dysfunction may be overrepresented in ADHD. 
This is important for barrier functions in both intestine and brain, and can further associate with 
neuroinflammation. Markers for permeability of intestinal barrier and BBB, such as Occludine, 
Claudines, JAMs, ZO-1, Zonulin, S100B can be measured in blood samples.  Due to the 
limitation of a sample direct resource from brain (e.g. CSF, brain tissue), animal model or in 
vitro model is a feasible alternative. To confirm the effects of Synbiotic 2000 found in Study 
III, we hope to collaborate with a similar RCT that is running in three sites in Europe 
(Germany, Spain and Hungary). Followed by Study IV of inflammation and SCFA profiles in 
ADHD, gut metabolomics will be conducted to explore other interesting microbiota 
metabolites, like bile acids. Another plan is to profile the gut microbiota with fecal samples, 
evaluate the biodiversity and abundance of microbes and detect the bacterial genes and 
functions. Shallow shotgun metagenomic sequencing was employed to obtain the whole 
genome of the organisms in the samples, data analyses are ongoing. To further study the role 
of microbiota, fecal transplantation from patients to germ-free animal model and oral 
administration of certain bacteria stain can be performed. Further, the neuroendocrine 
component (HPA axis) of GBA has not been explored in this thesis, but would be an interesting 
path to take on. 
Generally, in ADHD and the broader psychiatric field, diagnostic tools and treatments are 
limited. I hope our work will contribute a little to the understanding of the GBA in ADHD and 
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SNAP-IV 26-Item Teacher and Parent Rating Scale 
James M. Swanson, Ph.D., University of California, Irvine, CA 92715  
 
Patient/Client Name: ___________________________________________________________________________________       
Date of birth: ________________________________________________________________ Gender: ______________________ 
Grade: ________    Type of class: ____________________________________________ Class size: ____________________ 
Completed by: ______________________________________________________________  Date: __________________________ 
Physician Name: ___________________________________________________________ 
 
For each item, check the column which best describes this child/adolescent: 
 








  1.  Often fails to give close attention to details or makes careless mistakes  
in schoolwork or tasks 
    
  2.  Often has difficulty sustaining attention in tasks or play activities     
  3.  Often does not seem to listen when spoken to directly     
  4.  Often does not follow through on instructions and fails to finish  
schoolwork, chores, or duties  
    
  5.  Often has difficulty organizing tasks and activities     
  6.  Often avoids, dislikes, or reluctantly engages in tasks requiring 
sustained mental effort 
    
  7.  Often loses things necessary for activities (e.g., toys, school 
assignments, pencils or books 
    
  8.  Often is distracted by extraneous stimuli     
  9.  Often is forgetful in daily activities     
10. Often fidgets with hands or feet or squirms in seat     
11. Often leaves seat in classroom or in other situations in which remaining 
seated is expected 
    
12. Often runs about or climbs excessively in situations in which it is 
inappropriate 
    
13. Often has difficulty playing or engaging in leisure activities quietly     
14. Often is “on the go” or often acts as if “driven by a motor”     
15. Often talks excessively     
16. Often blurts out answers before questions have been completed     
17. Often has difficulty awaiting turn     
18. Often interrupts or intrudes on others (e.g., butts into conversations/ 
games 
    
19. Often loses temper     
20. Often argues with adults     
21. Often actively defies or refuses adult requests or rules     
22. Often deliberately does things that annoy other people     
23. Often blames others for his or her mistakes or misbehaviour     
24. Often is touchy or easily annoyed by others     
25. Often is angry and resentful     
26. Often is spiteful or vindictive     
Scoring guide for SNAP-IV 26-Item Teacher and Parent Rating Scale 
 
The SNAP-IV 26-item scale is an abbreviated version of the Swanson, Nolan, and Pelham 
(SNAP) Questionnaire (Swanson, 1992; Swanson et al., 1983).  Items from the DSM-IV 
criteria for attention-deficit/hyperactivity disorder (ADHD) are included for the two 
subsets of symptoms: Inattention (items 1–9) and Hyperactivity/Impulsivity (items 10–
18).  Also, items from the DSM-IV criteria for oppositional defiant disorder (ODD) are 
included (items 19–26) because ODD is often present in children with ADHD.  
 
Symptom severity is rated on a 4-point scale.  Responses are scored as follows:   
Not at all = 0  
Just a little = 1  
Quite a bit = 2 
Very much = 3 
 
The scores in each of the three subsets (inattention, hyperactivity/impulsivity, and 
opposition/defiance) are totalled.  A suggested scoring guideline is below: 
 
Questions 1 – 9: Inattention Subset 
< 13/27 = Symptoms not clinically significant  
13 – 17 = Mild symptoms  
18 – 22 = Moderate symptoms  
23 – 27 = Severe symptoms  
 
Questions 10 – 18: Hyperactivity/Impulsivity Subset 
<13/27 = Symptoms not clinically significant 
13 – 17 = Mild symptoms 
18 – 22 = Moderate symptoms 
23 – 27 = Severe symptoms 
 
Questions 19 – 26: Opposition/Defiance Subset 
< 8/24 = Symptoms not clinically significant 
8 – 13 = Mild symptoms 
14 – 18 = Moderate symptoms 
19 – 24 = Severe symptoms 
 
Suggested Targets: 
 <13/27 for inattention  
<13/27 for hyperactivity/impulsivity 
<8/24 for oppositional defiant disorder 
 
If desired, the average rating for each subset can be calculated by totalling the scores for 
the items in the subset and dividing by the number of items.  The average can be compared 






ADULT ADHD SELF-REPORT SCALE (ASRS-V1.1) SYMPTOM CHECKLIST INSTRUCTIONS
Description: 
The Symptom Checklist is an instrument consisting of the 18 DSM-IV-TR criteria. Six of the 18 questions 
were found to be the most predictive of symptoms consistent with ADHD. These six questions are the basis 
for the ASRS-V1.1 screener and are also Part A of the Symptom Checklist. Part B of the Symptom Checklist 
contains the remaining 12 questions.
Instructions:
Symptoms
1.  Ask the patient to complete both Part A and Part B of the Symptom Checklist by marking an X in the 
box that most closely represents the frequency of occurrence of each of the symptoms.
2.  Score Part A. If four or more marks appear under Often/Very Often then the patient has symptoms 
highly consistent with ADHD in adults and further investigation is warranted.
3.  The frequency scores on Part B provide additional cues and can serve as further probes into the patient’s 
symptoms. Pay particular attention to marks appearing under Often/Very Often. The frequency-based 
response is more sensitive with certain questions. No total score or diagnostic likelihood is utilized 
for the 12 questions. It has been found that the six questions in Part A are the most predictive of the 
disorder and are best for use as a screening instrument.
Impairments
1.  Review the entire Symptom Checklist with your patients and evaluate the level of impairment associated 
with the symptom.
2. Consider work/school, social and family settings.
3.  Symptom frequency is often associated with symptom severity, therefore the Symptom Checklist may 
also aid in the assessment of impairments. If your patients have frequent symptoms, you may want to 
ask them to describe how these problems have affected the ability to work, take care of things at home, 
or get along with other people such as their spouse/significant other.
History
1.  Assess the presence of these symptoms or similar symptoms in childhood. Adults who have ADHD need 
not have been formally diagnosed in childhood. In evaluating a patient’s history, look for evidence of 
early-appearing and long-standing problems with attention or self-control. Some significant symptoms 
should have been present in childhood, but full symptomology is not necessary.
References:
1. Schweitzer JB et al. Med Clin North Am. 2001;85(3),10-11:757-777.
2. Barkley RA. Attention Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment. 2nd ed. 1998.
3. Biederman J, et al. Am J Psychiatry. 1993;150:1792-1798.
4. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders.Fourth Edition, Text Revision. Washington, DC, American Psychiatric   
   Association. 2000:85-93. 
© 2003 World Health Organization. Reprinted with permission. 




ADULT ADHD SELF-REPORT SCALE (ASRS-V1.1) SYMPTOM CHECKLIST
  Please answer the questions below, rating yourself on each of the criteria shown using the scale on the right  
 side of the page. As you answer each question, place an X in the box that best describes how you have felt and  
 conducted yourself over the past 6 months. Please give this completed  checklist to your healthcare professional  
 to discuss during your appointment
   PART A
  1.  How often do you have trouble wrapping up the final details of a project, once the  
    challenging parts have been done?
  2.  How often do you have difficulty getting things in order when you have to do a task that  
    requires organization?
  3.  How often do you have problems remembering appointments or obligations? 
  4.  When you have a task that requires a lot of thought, how often do you avoid or delay getting  
    started?
  5.  How often do you fidget or squirm with your hands or feet when you have to sit down for a  
    long time?
  6.  How often do you feel overly active and compelled to do things, like you were driven by a  
    motor?
    PART B
  7.  How often do you make careless mistakes when you have to work on a boring or difficult  
    project?
  8.  How often do you have difficulty keeping your attention when you are doing boring or  
    repetitive work?
  9.  How often do you have difficulty concentrating on what people say to you, even when they  
    are speaking to you directly?
 10. How often do you misplace or have difficulty finding things at home or at work?     
 11. How often are you distracted by activity or noise around you?     
 12. How often do you leave your seat in meetings or in other situations in which you are  
    expected to stay seated?
 13. How often do you feel restless or fidgety?     
 14. How often do you have difficulty unwinding and relaxing when you have time to yourself?     
 15. How often do you find yourself talking too much when you are in social situations?     
 16. When you’re in a conversation, how often do you find yourself finishing the sentences of the  
    people you are talking to, before they can finish it themselves?
 17. How often do you have difficulty waiting your turn in situations when turn taking is required?     





















Date of Birth:    MRN/File No:
Physician Name:    Date:
8.25Toolkit
WEISS FUNCTIONAL IMPAIRMENT RATING SCALE (WFIRS) INSTRUCTIONS
Purpose
■  ADHD symptoms and actual impairment overlap but are distinct concepts. It is important to measure 
both since some patients are highly symptomatic but not impaired or vice versa
■  This scale contains those items that are most likely to represent the patient's target of treatment. 
Therefore, the use of the scale before and after treatment can allow the clinician to determine not only 
if the ADHD has improved, but if the patient's functional difficulties are also better.
■  This instrument has been translated into 18 languages. It has been used in many studies and is 
psychometrically validated. This is the only measure of functional impairment that looks at specific 
domains and has been validated in the ADHD population.
Design and Validation Information
Scoring The instrument uses a Likert scale such that any item rating 2 or 3 is clinically impaired. The scale 
can be scored by looking at the total score or by creating a mean score for the total score/number items 
for each domain, omitting those rated not applicable. For clinical purposes, when defining impairment for 
DSM-IV, clinicians can consider that any domain with at least two items scored 2, one item scored 3 or a 
mean score >1.5 is impaired.
Validation The scale has been psychometrically validated with an internal consistency >.8 for each 
domain and for the scale as a whole. It has moderate convergent validity (0.6) with other measures 
of functioning (i.e. Columbia Impairment Scale and the Global Assessment of Functioning (GAF). It 
has moderate discriminating validity (0.4) from symptoms pre-treatment (i.e. ADHD-Rating Scale) and 
quality of life (CHIP). The domains have been confirmed by factor analysis, although the domain of 
school functioning separates into learning and behaviour. The scale is highly sensitive to change with 
treatment and, in particular, significantly correlated to change in ADHD symptoms (40% change) and 
overall psychopathology. Each anchor point on the Likert scale represents approximately one standard 
deviation(SD). A total score change of 13 would be considered a significant improvement or about half 
a SD. The change obtained in treatment is typically one full SD. The mean score for risky behaviour in 
children is 0.5 but increases with age. For adolescents the mean score is 1.
Copyright Information
This scale is copyrighted by Margaret Danielle Weiss, MD PhD, at the University of British Columbia. 
The scale can be used by clinicians and researchers free of charge and can be posted on the internet or 
replicated as needed. Please contact Dr. Weiss at margaret.weiss@icloud.com if you wish to post the scale 
on the internet, use it in research or plan to create a translation. 
8.27Toolkit
 
             
               
 
WEISS FUNCTIONAL IMPAIRMENT RATING SCALE – SELF REPORT (WFIRS-S) 
Work:        Full time      Part time      Other  ___________________          School:     Full time      Part time 
Circle the number for the rating that best describes how your emotional or behavioural problems have affected each item in the last month. 
Patient Name:
Date of Birth:    MRN/File No:
Physician Name:    Date:
   Never or Sometimes Often or Very often or    
   not at all or somewhat much very much n/a
 A  FAMILY 
 1 Having problems with family  0 1 2 3 n/a
 2 Having problems with spouse/partner  0 1 2 3 n/a
 3 Relying on others to do things for you  0 1 2 3 n/a
 4 Causing fighting in the family  0 1 2 3 n/a
 5 Makes it hard for the family to have fun together 0 1 2 3 n/a
 6 Problems taking care of your family  0 1 2 3 n/a
 7 Problems balancing your needs against those of your family 0 1 2 3 n/
 8 Problems losing control with family  0 1 2 3 n/a
 B WORK
 1 Problems performing required duties  0 1 2 3 n/a
 2 Problems with getting your work done efficiently 0 1 2 3 n/a
 3 Problems with your supervisor  0 1 2 3 n/a
 4 Problems keeping a job  0 1 2 3 n/a
 5 Getting fired from work  0 1 2 3 n/a
 6 Problems working in a team  0 1 2 3 n/a
 7 Problems with your attendance  0 1 2 3 n/a
 8 Problems with being late  0 1 2 3 n/a
 9 Problems taking on new tasks  0 1 2 3 n/a
 10 Problems working to your potential  0 1 2 3 n/a
 11 Poor performance evaluations  0 1 2 3 n/a
 C SCHOOL
 1 Problems taking notes  0 1 2 3 n/a
 2 Problems completing assignments  0 1 2 3 n/a
 3 Problems getting your work done efficiently 0 1 2 3 n/a
 4 Problems with teachers  0 1 2 3 n/a
 5 Problems with school administrators  0 1 2 3 n/a
 6 Problems meeting minimum requirements to stay in school 0 1 2 3 n/a
 7 Problems with attendance  0 1 2 3 n/a
 8 Problems with being late  0 1 2 3 n/a
 9 Problems with working to your potential 0 1 2 3 n/a
 10 Problems with inconsistent grades  0 1 2 3 n/a
 D LIFE SKILLS
 1 Excessive or inappropriate use of internet, video games or TV 0 1 2 3 n/a
 2 Problems keeping an acceptable appearance 0 1 2 3 n/a
 3 Problems getting ready to leave the house 0 1 2 3 n/a
 4 Problems getting to bed  0 1 2 3 n/a
 5 Problems with nutrition  0 1 2 3 n/a
8.28 Version: November 2014. Refer to www.caddra.ca for latest updates. 
    Never or Sometimes Often or Very often or    
    not at all or somewhat much very much n/a 
 6 Problems with sex  0 1 2 3 n/a
 7 Problems with sleeping  0 1 2 3 n/a
 8 Getting hurt or injured  0 1 2 3 n/a
 9 Avoiding exercise  0 1 2 3 n/a
 10 Problems keeping regular appointments with doctor/dentist 0 1 2 3 n/a
 11 Problems keeping up with household chores 0 1 2 3 n/a
 12 Problems managing money  0 1 2 3 n/a
 E SELF-CONCEPT
 1 Feeling bad about yourself  0 1 2 3 n/a
 2 Feeling frustrated with yourself  0 1 2 3 n/a
 3 Feeling discouraged  0 1 2 3 n/a
 4 Not feeling happy with your life  0 1 2 3 n/a
 5 Feeling incompetent  0 1 2 3 n/a
 F  SOCIAL
 1 Getting into arguments  0 1 2 3 n/a
 2 Trouble cooperating  0 1 2 3 n/a
 3 Trouble getting along with people  0 1 2 3 n/a
 4 Problems having fun with other people 0 1 2 3 n/a
 5 Problems participating in hobbies  0 1 2 3 n/a
 6 Problems making friends  0 1 2 3 n/a
 7 Problems keeping friends  0 1 2 3 n/a
 8 Saying inappropriate things  0 1 2 3 n/a
 9 Complaints from neighbours  0 1 2 3 n/a 
  G  RISK
 1 Aggressive driving  0 1 2 3 n/a
 2 Doing other things while driving  0 1 2 3 n/a
 3 Road rage  0 1 2 3 n/a
 4 Breaking or damaging things  0 1 2 3 n/a
 5 Doing things that are illegal  0 1 2 3 n/a
 6 Being involved with the police  0 1 2 3 n/a
 7 Smoking cigarettes  0 1 2 3 n/a
 8 Smoking marijuana  0 1 2 3 n/a
 9 Drinking alcohol  0 1 2 3 n/a
 10 Taking "street" drugs  0 1 2 3 n/a
 11 Sex without protection (birth control, condom) 0 1 2 3 n/a
 12 Sexually inappropriate behaviour  0 1 2 3 n/a
 13 Being physically aggressive  0 1 2 3 n/a
 14 Being verbally aggressive  0 1 2 3 n/a
WFIRS-S 2/2
SCORING:
1. Number of items scored 2 or 3
    or
2. Total score
    or
3. Mean score 
This scale is copyrighted by Margaret Danielle Weiss, MD PhD, at the University of British Columbia. The scale can be used by clinicians and 
researchers free of charge and can be posted on the internet or replicated as needed. Please contact Dr. Weiss at margaret.weiss@icloud.com if you 
wish to post the scale on the internet, use it in research or plan to create a translation. 















WEISS FUNCTIONAL IMPAIRMENT RATING SCALE – PARENT REPORT (WFIRS-P)
Your name: _____________________________________ Relationship to child: ______________________
Circle the number for the rating that best describes how your child's emotional or behavioural problems have 
affected each item in the last month. 
Patient Name:
Date of Birth:    MRN/File No:
Physician Name:    Date:
   Never or Sometimes Often or Very often or    
   not at all or somewhat much very much n/a
 A FAMILY 
 1 Having problems with brothers & sisters 0 1 2 3 n/a
 2 Causing problems between parents  0 1 2 3 n/a
 3 Takes time away from family members’ work or activities 0 1 2 3 n/a
 4 Causing fighting in the family  0 1 2 3 n/a
 5 Isolating the family from friends and social activities 0 1 2 3 n/a
 6 Makes it hard for the family to have fun together 0 1 2 3 n/a
 7 Makes parenting difficult  0 1 2 3 n/a
 8 Makes it hard to give fair attention to all family members 0 1 2 3 n/a
 9 Provokes others to hit or scream at him/her 0 1 2 3 n/a
 10 Costs the family more money  0 1 2 3 n/a
 B SCHOOL
  Learning
 1 Makes it difficult to keep up with schoolwork 0 1 2 3 n/a
 2 Needs extra help at school  0 1 2 3 n/a
 3 Needs tutoring  0 1 2 3 n/a
 4 Receives grades that are not as good as his/her ability 0 1 2 3 n/a
  Behaviour
 1 Causes problems for the teacher in the classroom 0 1 2 3 n/a
 2 Receives ”time-out” or removal from the classroom 0 1 2 3 n/a
 3 Having problems in the school yard  0 1 2 3 n/a
 4 Receives detentions (during or after school) 0 1 2 3 n/a
 5 Suspended or expelled from school  0 1 2 3 n/a
 6 Misses classes or is late for school  0 1 2 3 n/a
 C LIFE SKILLS
 1 Excessive use of TV, computer, or video games 0 1 2 3 n/a
 2 Keeping clean, brushing teeth, brushing hair, bathing, etc. 0 1 2 3 n/a
 3 Problems getting ready for school  0 1 2 3 n/a
WFIRS-P 1/2
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   Never or Sometimes Often or Very often or    
   not at all or somewhat much very much n/a
 4 Problems getting ready for bed  0 1 2 3 n/a
 5 Problems with eating (picky eater, junk food) 0 1 2 3 n/a
 6 Problems with sleeping  0 1 2 3 n/a
 7 Gets hurt or injured  0 1 2 3 n/a
 8 Avoids exercise  0 1 2 3 n/a
 9 Needs more medical care  0 1 2 3 n/a
 10 Has trouble taking medication, getting needles  
  or visiting the doctor/dentist  0 1 2 3 n/a
 D CHILD'S SELF-CONCEPT
 1 My child feels bad about himself/herself 0 1 2 3 n/a
 2 My child does not have enough fun  0 1 2 3 n/a
 3 My child is not happy with his/her life 0 1 2 3 n/a
 E SOCIAL ACTIVITIES
 1 Being teased or bullied by other children 0 1 2 3 n/a
 2 Teases or bullies other children  0 1 2 3 n/a
 3 Problems getting along with other children 0 1 2 3 n/a
 4 Problems participating in after-school activities (sports, music, clubs) 0 1 2 3 n/a
 5 Problems making new friends  0 1 2 3 n/a
 6 Problems keeping friends  0 1 2 3 n/a
 7 Difficulty with parties (not invited, avoids them, misbehaves) 0 1 2 3 n/a
 F  RISKY ACTIVITIES
 1 Easily led by other children (peer pressure) 0 1 2 3 n/a
 2 Breaking or damaging things  0 1 2 3 n/a
 3 Doing things that are illegal  0 1 2 3 n/a
 4 Being involved with the police  0 1 2 3 n/a
 5 Smoking cigarettes  0 1 2 3 n/a
 6 Taking illegal drugs  0 1 2 3 n/a
 7 Doing dangerous things  0 1 2 3 n/a
 8 Causes injury to others  0 1 2 3 n/a
 9 Says mean or inappropriate things  0 1 2 3 n/a
 10 Sexually inappropriate behaviour  0 1 2 3 n/a
SCORING:
1. Number of items scored 2 or 3
    or
2. Total score
    or
3. Mean score 
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 DO NOT WRITE IN THIS AREA
 A. Family    
 B. School    
  Learning    
  Behaviour     
 C. Life skills    
 D. Child's self-concept   
 E. Social activities   
 F. Risky activities   
     Total
This scale is copyrighted by Margaret Danielle Weiss, MD PhD, at the University of British Columbia. The scale can be used by clinicians and 
researchers free of charge and can be posted on the internet or replicated as needed. Please contact Dr. Weiss at margaret.weiss@icloud.com 
if you wish to post the scale on the internet, use it in research or plan to create a translation. 
 







The Adult Autism Spectrum Quotient (AQ)  
Ages 16+ 
 
SPECIMEN, FOR RESEARCH USE ONLY. 
 
For full details, please see: 
 
S. Baron-Cohen, S. Wheelwright, R. Skinner, J. Martin and E. Clubley, (2001) 
The Autism Spectrum Quotient (AQ) : Evidence from Asperger Syndrome/High 
Functioning Autism, Males and Females, Scientists and Mathematicians 




Name:...........................................     Sex:........................................... 
 
Date of birth:...................................     Today’s Date................................. 
 
 
How to fill out the questionnaire 
Below are a list of statements. Please read each statement very carefully and rate how strongly 
you agree or disagree with it by circling your answer. 
 
 DO NOT MISS ANY STATEMENT OUT. 
Examples 



























































3. If I try to imagine something, I find it very easy 










4. I frequently get so strongly absorbed in one 




















6. I usually notice car number plates or similar 










7. Other people frequently tell me that what I’ve 










8. When I’m reading a story, I can easily imagine 





















10. In a social group, I can easily keep track of 

































































16. I tend to have very strong interests which I get 





















18. When I talk, it isn’t always easy for others to get 






















20. When I’m reading a story, I find it difficult to 











































































27. I find it easy to “read between the lines” when 










28. I usually concentrate more on the whole picture, 





















30. I don’t usually notice small changes in a 































33. When I talk on the phone, I’m not sure when it’s 
































36. I find it easy to work out what someone is 










37. If there is an interruption, I can switch back to 





















39. People often tell me that I keep going on and on 










40. When I was young, I used to enjoy playing 










41. I like to collect information about categories of 
things (e.g. types of car, types of bird, types of 










42. I find it difficult to imagine what it would be 











































































49. I am not very good at remembering people’s 










50. I find it very easy to play games with children 
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"Totally correct" or "Pretty much right" to questions # 2, 4, 5, 6, 7, 9, 12, 13, 16, 18, 
19, 20, 21, 22, 23, 26, 33, 35 , 39, 41, 42, 43, 45, 46 give 1 point. 
 
"Does not match at all" or "Does not match" on question: 1, 3, 8, 10, 11, 14, 15, 17, 
24, 25, 27, 28, 29, 30, 31, 32, 34, 36, 37 , 38, 40, 44, 47, 48, 49, 50 give 1 point. 
 
Control group: 16.4 p. 80% of participants with AS had 32 p or more. 
 
 
It comprises 50 questions, made up of 10 questions assessing 5 different areas:  
social skill (items 1,11,13,15,22,36,44,45, 47,48);  
attention switching (items 2,4,10,16,25,32,34, 37,43,46);  
attention to detail (items 5,6,9,12,19,23,28, 29,30,49);  
communication (items 7,17,18,26,27,31,33, 35,38,39);  
imagination (items 3,8,14,20,21,24,40,41, 42,50). 
 
 










Almost	never		 Sometimes	 About	half	the	time	 Most	of	the	time		 Almost	always		
     0-10%    11-35%          36-65%          66-90%       91-100% 
	
	
________1)	I	have	difficulty	making	sense	out	of	my	feelings			
	
________2)	I	am	confused	about	how	I	feel.			
	
________3)	When	I	am	upset,	I	have	difficulty	getting	work	done.			
	
________4)	When	I	am	upset,	I	become	out	of	control.			
________5)	When	I	am	upset,	I	believe	that	I	will	remain	that	way	for	a	long	time.		 
	
________6)	When	I	am	upset,	I	believe	that	I’ll	end	up	feeling	very	depressed.			
	
________7)	When	I	am	upset,	I	have	difficulty	focusing	on	other	things.			
	
________8)	When	I	am	upset,	I	feel	out	of	control.			
	
________9)	When	I	am	upset,	I	feel	ashamed	with	myself	for	feeling	that	way.			
	
________10)	When	I	am	upset,	I	feel	like	I	am	weak.		
	
________11)	When	I	am	upset,	I	have	difficulty	controlling	my	behaviors.		
	
________12)	When	I	am	upset,	I	believe	that	there	is	nothing	I	can	do	to	make	myself	feel	
better.		
	
________13)	When	I	am	upset,	I	become	irritated	with	myself	for	feeling	that	way.		
	
________14)	When	I	am	upset,	I	start	to	feel	very	bad	about	myself.		
	
________15)	When	I	am	upset,	I	have	difficulty	thinking	about	anything	else.		
	
________16)	When	I	am	upset,	my	emotions	feel	overwhelming.		
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